```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:58:42 ON 15 MAR 2009

=> fil .bec
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.22       0.22

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,
       ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 21:59:18 ON 15 MAR 2009
ALL COPYRIGHTS AND RESTRICTIONS APPLY.  SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s thymidylate synthase# or thya
FILE 'MEDLINE'
          4825 THYMIDYLATE
        113608 SYNTHASE#
          3978 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
           180 THYA
L1        4077 THYMIDYLATE SYNTHASE# OR THYA

FILE 'SCISEARCH'
          5729 THYMIDYLATE
        138898 SYNTHASE#
          4456 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
           111 THYA
L2        4506 THYMIDYLATE SYNTHASE# OR THYA

FILE 'LIFESCI'
          1313 "THYMIDYLATE"
         33454 SYNTHASE#
           963 THYMIDYLATE SYNTHASE#
                 ("THYMIDYLATE"(W)SYNTHASE#)
           103 THYA
L3        1016 THYMIDYLATE SYNTHASE# OR THYA

FILE 'BIOTECHDS'
           232 THYMIDYLATE
          7582 SYNTHASE#
           177 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
            60 THYA
L4         218 THYMIDYLATE SYNTHASE# OR THYA

FILE 'BIOSIS'
          6055 THYMIDYLATE
        125880 SYNTHASE#
          3757 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
           185 THYA
L5        3874 THYMIDYLATE SYNTHASE# OR THYA

FILE 'EMBASE'
          4747 "THYMIDYLATE"
        114866 SYNTHASE#
          4064 THYMIDYLATE SYNTHASE#
                 ("THYMIDYLATE"(W)SYNTHASE#)
```

```
           134 THYA
L6        4135 THYMIDYLATE SYNTHASE# OR THYA

FILE 'HCAPLUS'
          6316 THYMIDYLATE
        122782 SYNTHASE#
          3887 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
           280 THYA
L7        4058 THYMIDYLATE SYNTHASE# OR THYA

FILE 'NTIS'
            20 THYMIDYLATE
           304 SYNTHASE#
             5 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
             2 THYA
L8           7 THYMIDYLATE SYNTHASE# OR THYA

FILE 'ESBIOBASE'
          1803 THYMIDYLATE
         58549 SYNTHASE#
          1533 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
            69 THYA
L9        1560 THYMIDYLATE SYNTHASE# OR THYA

FILE 'BIOTECHNO'
          1423 THYMIDYLATE
         29457 SYNTHASE#
          1155 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
            74 THYA
L10       1195 THYMIDYLATE SYNTHASE# OR THYA

FILE 'WPIDS'
           291 THYMIDYLATE
          7638 SYNTHASE#
           202 THYMIDYLATE SYNTHASE#
                 (THYMIDYLATE(W)SYNTHASE#)
            42 THYA
L11        230 THYMIDYLATE SYNTHASE# OR THYA

TOTAL FOR ALL FILES
L12      24876 THYMIDYLATE SYNTHASE# OR THYA

=> s (biologic? or microorganism?)(10a)(control? or containment or abalat?)
FILE 'MEDLINE'
        862799 BIOLOGIC?
         43223 MICROORGANISM?
       2560565 CONTROL?
          8002 CONTAINMENT
             4 ABALAT?
L13      13561 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
               ABALAT?)

FILE 'SCISEARCH'
        431305 BIOLOGIC?
         58817 MICROORGANISM?
       2093908 CONTROL?
          8514 CONTAINMENT
            11 ABALAT?
```

```
L14      25622 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
               ABALAT?)

FILE 'LIFESCI'
        172952 BIOLOGIC?
         49464 MICROORGANISM?
        509936 CONTROL?
          1252 CONTAINMENT
             2 ABALAT?
L15      22965 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
               ABALAT?)

FILE 'BIOTECHDS'
         63301 BIOLOGIC?
         29908 MICROORGANISM?
         73069 CONTROL?
           426 CONTAINMENT
             0 ABALAT?
L16       6558 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
               ABALAT?)

FILE 'BIOSIS'
        508841 BIOLOGIC?
       3371749 MICROORGANISM?
       2464549 CONTROL?
          3754 CONTAINMENT
            20 ABALAT?
L17      55026 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
               ABALAT?)

FILE 'EMBASE'
        412230 BIOLOGIC?
        136329 MICROORGANISM?
       3826864 CONTROL?
          5681 CONTAINMENT
             6 ABALAT?
L18       8724 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
               ABALAT?)

FILE 'HCAPLUS'
       4038046 BIOLOGIC?
        712020 BIOL
       4445630 BIOLOGIC?
                 (BIOLOGIC? OR BIOL)
        182630 MICROORGANISM?
       2784598 CONTROL?
         14634 CONTAINMENT
             4 ABALAT?
L19      62707 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
               ABALAT?)

FILE 'NTIS'
         54339 BIOLOGIC?
          9479 MICROORGANISM?
        347093 CONTROL?
         12884 CONTAINMENT
             5 ABALAT?
L20       2800 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
               ABALAT?)

FILE 'ESBIOBASE'
        207927 BIOLOGIC?
```

```
        160352 MICROORGANISM?
        753246 CONTROL?
          1473 CONTAINMENT
             0 ABALAT?
L21       17489 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
                ABALAT?)

FILE 'BIOTECHNO'
         93054 BIOLOGIC?
         18193 MICROORGANISM?
        620701 CONTROL?
           536 CONTAINMENT
             1 ABALAT?
L22        5894 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
                ABALAT?)

FILE 'WPIDS'
        199726 BIOLOGIC?
          1411 BIOL
        200793 BIOLOGIC?
                 (BIOLOGIC? OR BIOL)
         63214 MICROORGANISM?
       3302531 CONTROL?
         14741 CONTAINMENT
             2 ABALAT?
L23        9054 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
                ABALAT?)

TOTAL FOR ALL FILES
L24      230400 (BIOLOGIC? OR MICROORGANISM?)(10A)(CONTROL? OR CONTAINMENT OR
                ABALAT?)

=> s l12 and l24
FILE 'MEDLINE'
L25           5 L1 AND L13

FILE 'SCISEARCH'
L26           8 L2 AND L14

FILE 'LIFESCI'
L27           3 L3 AND L15

FILE 'BIOTECHDS'
L28           6 L4 AND L16

FILE 'BIOSIS'
L29           5 L5 AND L17

FILE 'EMBASE'
L30           7 L6 AND L18

FILE 'HCAPLUS'
L31          17 L7 AND L19

FILE 'NTIS'
L32           0 L8 AND L20

FILE 'ESBIOBASE'
L33           4 L9 AND L21

FILE 'BIOTECHNO'
L34           2 L10 AND L22
```

```
FILE 'WPIDS'
L35          3 L11 AND L23

TOTAL FOR ALL FILES
L36         60 L12 AND L24

=> s l24 and (thymidine or thymine)
FILE 'MEDLINE'
         66784 THYMIDINE
         12060 THYMINE
L37         31 L13 AND (THYMIDINE OR THYMINE)

FILE 'SCISEARCH'
         32015 THYMIDINE
          8449 THYMINE
L38         30 L14 AND (THYMIDINE OR THYMINE)

FILE 'LIFESCI'
         13496 THYMIDINE
          3113 THYMINE
L39         14 L15 AND (THYMIDINE OR THYMINE)

FILE 'BIOTECHDS'
          3834 THYMIDINE
          1052 THYMINE
L40         24 L16 AND (THYMIDINE OR THYMINE)

FILE 'BIOSIS'
         60004 THYMIDINE
         10058 THYMINE
L41         36 L17 AND (THYMIDINE OR THYMINE)

FILE 'EMBASE'
         58777 THYMIDINE
          9415 THYMINE
L42         30 L18 AND (THYMIDINE OR THYMINE)

FILE 'HCAPLUS'
         56856 THYMIDINE
         20116 THYMINE
L43        128 L19 AND (THYMIDINE OR THYMINE)

FILE 'NTIS'
           552 THYMIDINE
           236 THYMINE
L44          5 L20 AND (THYMIDINE OR THYMINE)

FILE 'ESBIOBASE'
         12605 THYMIDINE
          2390 THYMINE
L45         10 L21 AND (THYMIDINE OR THYMINE)

FILE 'BIOTECHNO'
         17232 THYMIDINE
          3243 THYMINE
L46         14 L22 AND (THYMIDINE OR THYMINE)

FILE 'WPIDS'
          4373 THYMIDINE
          2226 THYMINE
L47         19 L23 AND (THYMIDINE OR THYMINE)
```

```
TOTAL FOR ALL FILES
L48        341 L24 AND (THYMIDINE OR THYMINE)

=> s (l36 or l48) not 2003-2009/py
FILE 'MEDLINE'
       4037483 2003-2009/PY
L49         22 (L25 OR L37) NOT 2003-2009/PY

FILE 'SCISEARCH'
       7579956 2003-2009/PY
                 (20030000-20099999/PY)
L50         21 (L26 OR L38) NOT 2003-2009/PY

FILE 'LIFESCI'
       1052983 2003-2009/PY
L51          8 (L27 OR L39) NOT 2003-2009/PY

FILE 'BIOTECHDS'
        148657 2003-2009/PY
L52         18 (L28 OR L40) NOT 2003-2009/PY

FILE 'BIOSIS'
       3618282 2003-2009/PY
L53         27 (L29 OR L41) NOT 2003-2009/PY

FILE 'EMBASE'
       3485325 2003-2009/PY
L54         20 (L30 OR L42) NOT 2003-2009/PY

FILE 'HCAPLUS'
       7998614 2003-2009/PY
L55         86 (L31 OR L43) NOT 2003-2009/PY

FILE 'NTIS'
        104791 2003-2009/PY
L56          5 (L32 OR L44) NOT 2003-2009/PY

FILE 'ESBIOBASE'
       2059486 2003-2009/PY
L57          7 (L33 OR L45) NOT 2003-2009/PY

FILE 'BIOTECHNO'
        122467 2003-2009/PY
L58         13 (L34 OR L46) NOT 2003-2009/PY

FILE 'WPIDS'
       6715892 2003-2009/PY
L59          5 (L35 OR L47) NOT 2003-2009/PY

TOTAL FOR ALL FILES
L60        232 (L36 OR L48) NOT 2003-2009/PY

=> dup rem l60
PROCESSING COMPLETED FOR L60
L61         155 DUP REM L60 (77 DUPLICATES REMOVED)

=> d tot

L61   ANSWER 1 OF 155  BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI    Identifying nucleic acid ligands photocrosslinking to target from nucleic
      acids containing photoreactive groups, by modification of systematic
```

evolution of ligands by exponential enrichment method, termed photoSELEX; recombinant basic fibroblast growth factor ligand screening for use in diagnosis

AU GOLD L; SMITH J D; KOCH T; GOLDEN M
AN 2002-09653 BIOTECHDS
PI WO 2002006510 24 Jan 2002

L61 ANSWER 2 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Measuring abundance and expression of indicator and effector genes within biotreatment system, by sampling activated sludges and effecting polymerase chain reaction amplification of indicator and effector gene combinations from sample; reverse transcription-polymerase chain reaction and DNA primer for activated sludge monitoring

AU CARSON D B; RICE J F
AN 2003-07131 BIOTECHDS
PI WO 2002085791 31 Oct 2002

L61 ANSWER 3 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI New cyclic nucleotide phosphodiesterase polypeptides such as PDE8A, PDE7A3, TbPDE2A, TbPDE2B, TbPDE2C or TbPDE2E, that are involved in T cell activation, useful for diagnosis and treatment of immune disorders; recombinant enzyme gene production, vector expression in host cell, antibody, sense, antisense molecule, agonist, antagonist and polymerase chain reaction useful in disease gene therapy, drug screening and vaccine

AU BEAVO J A; SEEBECK T; SODERLING S H; RASCON A; ZORAGHI R; KUNZ S; GONG K; GLAVAS N
AN 2002-12822 BIOTECHDS
PI WO 2002022661 21 Mar 2002

L61 ANSWER 4 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Papovavirus-derived episomal vector and replication control expression system using a mutant large T antigen for human gene therapy and protein production
SO U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 935,368.
CODEN: USXXCO
IN Cooper, Mark J.
AN 2002:833420 HCAPLUS
DN 137:334050

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20020160516	A1	20021031	US 2002-43289	20020114
US 6339065	B1	20020115	US 1996-594299	19960130
US 5770374	A	19980623	US 1996-728608	19961010
WO 9859059	A1	19981230	WO 1998-US12777	19980619
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 20020031803	A1	20020314	US 2001-935368	20010824

L61 ANSWER 5 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Distinct nongenomic signal transduction pathways controlled by 17β-estradiol regulate DNA synthesis and cyclin D1 gene transcription in HepG2 cells
SO Molecular Biology of the Cell (2002), 13(10), 3720-3729
CODEN: MBCEEV; ISSN: 1059-1524

AU Marino, Maria; Acconcia, Filippo; Bresciani, Francesco; Weisz, Alessandro; Trentalance, Anna
AN 2002:818828 HCAPLUS
DN 138:231897

L61 ANSWER 6 OF 155 MEDLINE on STN DUPLICATE 2
TI Role of biological markers in the clinical outcome of colon cancer.
SO British journal of cancer, (2002 Oct 7) Vol. 87, No. 8, pp. 868-75. Journal code: 0370635. ISSN: 0007-0920.
AU Nanni O; Volpi A; Frassineti G L; De Paola F; Granato A M; Dubini A; Zoli W; Scarpi E; Turci D; Oliverio G; Gambi A; Amadori D
AN 2002615329 MEDLINE

L61 ANSWER 7 OF 155 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on STN
AN 2002253271 ESBIOBASE
TI Role of biological markers in the clinical outcome of colon cancer
AU Nanni, O.; Volpi, A.; Frassineti, G.L.; De Paola, F.; Granato, A.M.; Dubini, A.; Zoli, W.; Scarpi, E.; Turci, D.; Oliverio, G.; Gambi, A.; Amadori, D.
CS Nanni, O.; Volpi, A.; Frassineti, G.L.; De Paola, F.; Granato, A.M.; Dubini, A.; Zoli, W.; Scarpi, E.; Turci, D.; Oliverio, G.; Gambi, A.; Amadori, D. (Department of Medical Ontology, Pierantoni Hospital, Via Forlanini 34, 47100 Forli (IT))
SO British Journal of Cancer (7 Oct 2002) Volume 87, Number 8, pp. 868-875, 63 refs.
CODEN: BJCAAI ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6600569
CY United Kingdom
DT Journal; Article
LA English
SL English
ED Entered STN: 1 Feb 2009
Last updated on STN: 1 Feb 2009

L61 ANSWER 8 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Exploitation of genetically modified inoculants for industrial ecology applications;
vector-mediated gene transfer and expression in host cell for strain improvement and potential bioremediation or biological control agent
SO ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICR; (2002) 81, 1-4, 599-606 ISSN: 0003-6072
AU MORRISSEY JP; WALSH UF; O'DONNELL A; MOENNE-LOCCOZ Y; O'GARA F
AN 2002-14785 BIOTECHDS

L61 ANSWER 9 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Controlled aggregation of azobenzene based on DNA-mimetics at the air-water interface
SO International Journal of Nanoscience (2002), 1(5 & 6), 597-601
CODEN: IJNNAJ; ISSN: 0219-581X
AU Ijiro, Kuniharu; Matsumoto, Jin; Morisue, Mitsuhiko; Shimomura, Masatsugu
AN 2004:230627 HCAPLUS
DN 141:239194

L61 ANSWER 10 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI RecQ helicases and genome stability: lessons from model organisms and human disease
SO Swiss Medical Weekly (2002), 132(31/32), 433-442
CODEN: SMWWAI; ISSN: 1424-7860
AU Bjergbaek, Lotte; Cobb, Jennifer A.; Gasser, Susan M.
AN 2003:46641 HCAPLUS

DN 138:269186

L61 ANSWER 11 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Genetic and molecular control of folate-homocysteine metabolism in mutant mice
SO Mammalian Genome (2002), 13(5), 259-267
CODEN: MAMGEC; ISSN: 0938-8990
AU Ernest, Sheila; Christensen, Benedicte; Gilfix, Brian M.; Mamer, Orval A.; Hosack, Angela; Rodier, Mitchell; Colmenares, Clemencia; McGrath, James; Bale, Allen; Balling, Rudi; Sankoff, David; Rosenblatt, David S.; Nadeau, Joseph H.
AN 2002:429880 HCAPLUS
DN 137:246047

L61 ANSWER 12 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Identification of Novel E2F1-Regulated Genes by Microarray
SO Archives of Biochemistry and Biophysics (2002), 399(2), 212-224
CODEN: ABBIA4; ISSN: 0003-9861
AU Ma, Yihong; Croxton, Rhonda; Moorer, Ronnie L., Jr.; Cress, W. Douglas
AN 2002:176045 HCAPLUS
DN 137:120414

L61 ANSWER 13 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells
SO International Journal of Molecular Medicine (2002), 10(2), 193-199
CODEN: IJMMFG; ISSN: 1107-3756
AU Delmas, Dominique; Passilly-Degrace, Patricia; Jannin, Brigitte; Cherkaoui Malki, Mustapha; Latruffe, Norbert
AN 2002:622327 HCAPLUS
DN 138:147337

L61 ANSWER 14 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Remote electronic control of DNA hybridization through inductive coupling to an attached metal nanocrystal antenna;
DNA synthesis and oligonucleotide immobilization on gold nanocrystal support matrix for molecular study
SO Nature; (2002) 415, 6868, 152-55
CODEN: NATUAS ISSN: 0028-0836
AU Hamad-Schifferli K; Schwartz J J; Santos A T; Zhang S; *Jacobson J M
AN 2001-15626 BIOTECHDS

L61 ANSWER 15 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, (18 JUL 2002) Vol. 1587, No. 2-3, Sp. iss. SI, pp. 133-144.
ISSN: 0925-4439.
AU Pizzorno G (Reprint); Cao D L; Leffert J J; Russell R L; Zhang D K; Handschumacher R E
AN 2002:586160 SCISEARCH

L61 ANSWER 16 OF 155 MEDLINE on STN
TI alpha 2-Macroglobulin: a new component in the insulin-like growth factor/insulin-like growth factor binding protein-1 axis.
SO The Journal of biological chemistry, (2001 Nov 9) Vol. 276, No. 45, pp. 41668-74. Electronic Publication: 2001-08-23.
Journal code: 2985121R. ISSN: 0021-9258.
AU Westwood M; Aplin J D; Collinge I A; Gill A; White A; Gibson J M
AN 2001664326 MEDLINE

L61 ANSWER 17 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Structure Control on Photodimerization of Uracil and Thymine Moieties in Nucleolipid Langmuir-Blodgett Films by the Molecular Recognition Effect at the Air/Water Interface
SO Langmuir (2001), 17(7), 2228-2234
CODEN: LANGD5; ISSN: 0743-7463
AU Li, Chun; Huang, Jianguo; Liang, Yingqiu
AN 2001:156165 HCAPLUS
DN 134:349526

L61 ANSWER 18 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Serum stimulation and cell density regulate the proliferation of AsPC-1 cells through control of cyclin E and p27KIP1 expression
SO Anticancer Research (2001), 21(3B), 1885-1891
CODEN: ANTRD4; ISSN: 0250-7005
AU Horiguchi-Yamada, Junko; Yoshida, Seiya; Kuhara, Akiko; Aoki, Teruaki; Ohno, Tsuneya; Yamada, Hisashi
AN 2001:623917 HCAPLUS
DN 136:197787

L61 ANSWER 19 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI IGFBPs modulate IGF-I- and high glucose-controlled growth of human retinal endothelial cells
SO Journal of Endocrinology (2001), 171(2), 273-284
CODEN: JOENAK; ISSN: 0022-0795
AU Giannini, S.; Cresci, B.; Pala, L.; Ciucci, A.; Franchini, A.; Manuelli, C.; Fujita-Yamaguchi, Y.; Cappugi, P.; Zonefrati, R.; Rotella, C. M.
AN 2001:849253 HCAPLUS
DN 136:80319

L61 ANSWER 20 OF 155 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on STN
AN 2001093566 ESBIOBASE
TI Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: The role of VEGF 165
AU Gieschen, Holger L.; Spiro, Ira J.; Suit, Herman D.; Ancukiewicz, Marek; Willett, Christopher G; Ott, Mark J.; Rattner, David W.
CS Gieschen, Holger L. (Regional Cancer Center, Cape Cod Hospital, Hyannis, MA (US)); Spiro, Ira J.; Suit, Herman D.; Ancukiewicz, Marek; Willett, Christopher G (Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA (US)); Ott, Mark J. (Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA (US)); Rattner, David W. (Department of General Surgery, Massachusetts General Hospital, Boston, MA (US))
EMAIL: cwillett@partners.org
SO International Journal of Radiation Oncology Biology Physics (1 May 2001) Volume 50, Number 1, pp. 213-220, 37 refs.
CODEN: IOBPD3 ISSN: 0360-3016
DOI: 10.1016/S0360-3016(01)01445-6
PUI S0360301601014456
CY United States of America
DT Journal; Article
LA English
SL English
ED Entered STN: 1 Feb 2009
Last updated on STN: 1 Feb 2009

L61 ANSWER 21 OF 155 BIOTECHNO COPYRIGHT 2009 Elsevier Science B.V. on STN
TI Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: The role of VEGF.sub.1.sub.6.sub.5

SO International Journal of Radiation Oncology Biology Physics, (01 MAY 2001), 50/1 (213-220), 37 reference(s)
CODEN: IOBPD3 ISSN: 0360-3016
AU Kermani P.; Leclerc G.; Martel R.; Fareh J.
AN 2001:32318579 BIOTECHNO

L61 ANSWER 22 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Activation of transforming growth factor-β1 by hepatic stellate cells in vitro and consequences for cell proliferation and survival
SO Cells of the Hepatic Sinusoid (2001), 8, 191-194
CODEN: CHSIEL
AU Williams, E. J.; Cochrane, B. C.; Arthur, M. J. P.; Benyon, R. C.
AN 2001:630431 HCAPLUS
DN 135:327722

L61 ANSWER 23 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Loss of cyclin A and G1-cell cycle arrest are a prerequisite of ceramide-induced toxicity in human arterial endothelial cells
SO Cardiovascular Research (2001), 50(1), 97-107
CODEN: CVREAU; ISSN: 0008-6363
AU Spyridopoulos, I.; Mayer, P.; Shook, K. S.; Axel, D. I.; Viebahn, R.; Karsch, K. R.
AN 2001:219989 HCAPLUS
DN 135:58957

L61 ANSWER 24 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Flow-Induced DNA Synthesis Requires Signaling to a Translational Control Pathway
SO Journal of Surgical Research (2001), 97(1), 20-26
CODEN: JSGRA2; ISSN: 0022-4804
AU Kraiss, Larry W.; Ennis, Tina M.; Alto, Neal M.
AN 2001:292743 HCAPLUS
DN 135:135048

L61 ANSWER 25 OF 155 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI International Standards for hepatocyte growth factor/scatter factor: Initial assessment of candidate materials and their evaluation by multicentre collaborative study.
SO Journal of Immunological Methods, (1 December, 2001) Vol. 258, No. 1-2, pp. 1-11. print.
CODEN: JIMMBG. ISSN: 0022-1759.
AU Rafferty, B. [Reprint author]; Maile, P.; Rigsby, P.; Das, R. E. Gaines; Robinson, C. J.
AN 2001:557706 BIOSIS

L61 ANSWER 26 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Compositions and methods for controlled delivery of virus vectors
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
IN Levy, Robert J.; Jones, Peter L.
AN 2000:513547 HCAPLUS
DN 133:125280

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000043044	A1	20000727	WO 2000-US1193	20000119

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

L61 ANSWER 27 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
IN Levy, Robert J.; Crombleholme, Timothy; Vyavahare, Narendra
AN 2000:493425 HCAPLUS
DN 133:109939

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041732	A1	20000720	WO 2000-US1194	20000119
US 6333194	B1	20011225	US 2000-487854	20000119

PI WO 2000041732 A1 20000720 WO 2000-US1194 20000119
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 6333194 B1 20011225 US 2000-487854 20000119

L61 ANSWER 28 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI Genes expressed in Pseudomonas putida during colonization of a plant-pathogenic fungus
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY, (JUL 2000) Vol. 66, No. 7, pp. 2764-2772.
ISSN: 0099-2240.
AU Cooksey D A (Reprint); Lee S W
AN 2000:526153 SCISEARCH

L61 ANSWER 29 OF 155 MEDLINE on STN DUPLICATE 3
TI Engineered zinc finger proteins that respond to DNA modification by HaeIII and HhaI methyltransferase enzymes.
SO Journal of molecular biology, (2000 Jan 21) Vol. 295, No. 3, pp. 471-7.
Journal code: 2985088R. ISSN: 0022-2836.
AU Isalan M; Choo Y
AN 2000090946 MEDLINE

L61 ANSWER 30 OF 155 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on STN
AN 2000212380 ESBIOBASE
TI Engineered zinc finger proteins that respond to DNA modification by HaeIII and HhaI methyltransferase enzymes
AU Isalan, Mark; Choo, Yen
CS Isalan, Mark; Choo, Yen (Medical Research Council, Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH (GB)); Choo, Yen (Gendaq Ltd, 1-3 Burtonhole Lane, London NW7 1AD (GB))
EMAIL: choo@mrc-lmb.cam.ac.uk
SO Journal of Molecular Biology (21 Jan 2000) Volume 295, Number 3, pp. 471-477, 18 refs.
CODEN: JMOBAK ISSN: 0022-2836
DOI: 10.1006/jmbi.1999.3366
CY United Kingdom
DT Journal; Article
LA English
SL English

ED Entered STN: 31 Jan 2009
Last updated on STN: 31 Jan 2009

L61 ANSWER 31 OF 155 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on STN
AN 2000035594 ESBIOBASE
TI Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts
AU Wagner, Michaela S.; Stracke, Sylvia; Jehle, Peter M.; Keller, Frieder; Zellner, Dietmar; Baylink, David J.; Mohan, Subburaman
CS Wagner, Michaela S.; Stracke, Sylvia; Jehle, Peter M.; Keller, Frieder; Zellner, Dietmar; Baylink, David J.; Mohan, Subburaman (Jerry L. Pettis VA Medical Center, Depts. of Med., Biochem./Physiol., Loma Linda University, Loma Linda, CA (US)); Mohan, Subburaman (Musculoskel. Diseases Center (151), Jerry L. Pettis VA Medical Center, 11201 Benton Street, Loma Linda, CA 92357 (US))
EMAIL: mohans@ilvamc.va.gov
SO Nephron (2000) Volume 84, Number 2, pp. 158-166, 44 refs.
CODEN: NPRNAY ISSN: 0028-2766
CY Switzerland
DT Journal; Article
LA English
SL English
ED Entered STN: 31 Jan 2009
Last updated on STN: 31 Jan 2009

L61 ANSWER 32 OF 155 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN DUPLICATE 4
TI Telomerase: A therapeutic target for the third millennium?.
SO Critical Reviews in Oncology/Hematology, (May 2000) Vol. 34, No. 2, pp. 111-126.
Refs: 118
ISSN: 1040-8428 CODEN: CCRHEC
AU Lavelle, Francois (correspondence); Riou, Jean-Francois; Laoui, Abdelazize; Mailliet, Patrick; Lavelle, Francois (correspondence)
AN 2000152770 EMBASE

L61 ANSWER 33 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Transcriptional control elements of the rat thymidylate synthase promoter: evolutionary conservation of regulatory features
SO Experimental Cell Research (2000), 258(1), 53-64
CODEN: ECREAL; ISSN: 0014-4827
AU Lee, Yuandan; Johnson, Lee F.
AN 2000:426313 HCAPLUS
DN 134:1231

L61 ANSWER 34 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI Use of polymerase chain reaction (PCR) for the detection of vaccine contamination by infectious laryngotracheitis virus
SO VACCINE, (4 JUN 1999) Vol. 17, No. 20-21, pp. 2501-2506.
ISSN: 0264-410X.
AU Ottiger H P (Reprint); Vogtlin A; Bruckner L
AN 1999:511133 SCISEARCH

L61 ANSWER 35 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Re-evaluation of phytohormone-independent division of tobacco protoplast-derived cells
SO Plant Journal (1999), 17(5), 461-466
CODEN: PLJUED; ISSN: 0960-7412
AU Schell, Jeff; Bisseling, Ton; Dulz, Marion; Franssen, Henk; Fritze, Klaus;

John, Michael; Kleinow, Tatjana; Lessnick, Angela; Miklashevichs, Edvins; Pawlowski, Katharina; Rohrig, Horst; Van de Sande, Karin; Schmidt, Jurgen; Steinbiss, Hans-Henning; Stoll, Marion
AN 1999:246531 HCAPLUS
DN 131:85561

L61 ANSWER 36 OF 155 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI Differential mRNA expression levels and gene sequences of a putative carboxylesterase-like enzyme from two strains of the parasitoid Anisopteromalus calandrae (Hymenoptera: Pteromalidae).
SO Insect Biochemistry and Molecular Biology, (May, 1999) Vol. 29, No. 5, pp. 417-425. print.
CODEN: IBMBES. ISSN: 0965-1748.
AU Zhu, Yu-Cheng; Dowdy, Alan K.; Baker, James E. [Reprint author]
AN 1999:311364 BIOSIS

L61 ANSWER 37 OF 155 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI Detection of single-base substitution in an esterase gene and its linkage to malathion resistance in the parasitoid Anisopteromalus calandrae (Hymenoptera: Pteromalidae).
SO Pesticide Science, (April, 1999) Vol. 55, No. 4, pp. 398-404. print.
CODEN: PSSCBG. ISSN: 0031-613X.
AU Zhu, Yu-Cheng; Dowdy, Alan K.; Baker, James E. [Reprint author]
AN 1999:282896 BIOSIS

L61 ANSWER 38 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Elastin peptides and elastin receptor control proliferation of human gliomas
SO NATO Science Series, Series A: Life Sciences (1999), 311(Intermolecular Cross-Talk in Tumor Metastasis), 137-150
CODEN: NASAF2; ISSN: 1387-6686
AU Hinek, Aleksander; Rutka, James T.
AN 2000:75772 HCAPLUS
DN 132:346006

L61 ANSWER 39 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Genetically modified Pseudomonas strains with enhanced biocontrol activity;
recombinant Pseudomonas sp. for use as biological control agent
AU Ligon J M; Hill D S; Lam S T; Gaffney T D; Torkewitz N R; Stafford J M
AN 1998-08535 BIOTECHDS
PI WO 9824919 11 Jun 1998

L61 ANSWER 40 OF 155 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI New nucleobase derivatives of oligo:amide or oligo:(thio)ester - bind to nucleic acid, useful for gene expression control, as antiviral or anti-tumour agents, as diagnostic tools and in molecular biology
PI EP 816379 A2 19980107 (199806)* DE 21[1]
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DE 19635064 A1 19980108 (199807) DE
JP 10087634 A 19980407 (199824) JA 18
IN JORDAN S; KOSCH W; KRETSCHMER A; SCHWEMLER C; STROPP U

L61 ANSWER 41 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI D221 in Thymidylate Synthase Controls Conformation Change, and Thereby Opening of the Imidazolidine
SO Biochemistry (1998), 37(39), 13893-13901
CODEN: BICHAW; ISSN: 0006-2960
AU Sage, Carleton R.; Michelitsch, Melissa D.; Stout, Thomas J.; Biermann,

Donna; Nissen, Robert; Finer-Moore, Janet; Stroud, Robert M.
AN 1998:572701 HCAPLUS
DN 129:299609
OREF 129:61021a,61024a

L61 ANSWER 42 OF 155 MEDLINE on STN DUPLICATE 5
TI Endothelin-induced apoptosis of A375 human melanoma cells.
SO The Journal of biological chemistry, (1998 May 15) Vol. 273, No. 20, pp. 12584-92.
Journal code: 2985121R. ISSN: 0021-9258.
AU Okazawa M; Shiraki T; Ninomiya H; Kobayashi S; Masaki T
AN 1998241634 MEDLINE

L61 ANSWER 43 OF 155 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on STN
AN 1998120978 ESBIOBASE
TI Endothelin-induced apoptosis of A375 human melanoma cells
AU Ninomiya, Haruaki; Masaki, Tomoh; Okazawa, Makoto; Shiraki, Takuma; Kobayashi, Shigeo
CS Ninomiya, Haruaki; Masaki, Tomoh (Department of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606 (JP)); Masaki, Tomoh (Dept. of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606 (JP)); Okazawa, Makoto; Shiraki, Takuma; Kobayashi, Shigeo (Department of Neuroscience, Grad. Sch. Hum. and Environ. Studs., Kyoto University, Kyoto 606 (JP))
EMAIL: masaki@mfour.med.kyoto-u.ac.jp
SO Journal of Biological Chemistry (15 May 1998) Volume 273, Number 20, pp. 12584-12592, 40 refs.
CODEN: JBCHA3 ISSN: 0021-9258
DOI: 10.1074/jbc.273.20.12584
CY United States of America
DT Journal; Article
LA English
SL English
ED Entered STN: 31 Jan 2009
Last updated on STN: 31 Jan 2009

L61 ANSWER 44 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Expression of a retrovirally transduced gene under control of an internal housekeeping gene promoter does not persist due to methylation and is restored partially by 5-azacytidine treatment
SO Gene Therapy (1998), 5(10), 1299-1305
CODEN: GETHEC; ISSN: 0969-7128
AU Kuriyama, S.; Sakamoto, T.; Kikukawa, M.; Nakatani, T.; Toyokawa, Y.; Tsujinoue, H.; Ikenaka, K.; Fukui, H.; Tsujii, T.
AN 1998:659428 HCAPLUS
DN 130:32763

L61 ANSWER 45 OF 155 MEDLINE on STN DUPLICATE 6
TI Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing.
SO Gene therapy, (1998 May) Vol. 5, No. 5, pp. 614-20.
Journal code: 9421525. ISSN: 0969-7128.
AU Fife K; Bower M; Cooper R G; Stewart L; Etheridge C J; Coombes R C; Buluwela L; Miller A D
AN 1999014599 MEDLINE

L61 ANSWER 46 OF 155 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on STN
AN 1998127697 ESBIOBASE
TI Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing

AU Fife, K.; Bower, M.; Coombes, R.C.; Cooper, R.G.; Stewart, L.; Etheridge, C.J.; Miller, A.D.; Buluwela, L.
CS Fife, K.; Bower, M.; Coombes, R.C. (Department of Medical Oncology, Charing Cross Westminster Med. Sch., St Dunstan's Road, London W6 8RP (GB)); Cooper, R.G.; Stewart, L.; Etheridge, C.J.; Miller, A.D. (Department of Chemistry, Imp. Coll. Sci., Technol. and Med., London (GB)); Buluwela, L. (Department of Biochemistry, Charing Cross Westminster Med. Sch.)
SO Gene Therapy (1998) Volume 5, Number 5, pp. 614-620, 33 refs.
CODEN: GETHEC ISSN: 0969-7128
CY United Kingdom
DT Journal; Article
LA English
SL English
ED Entered STN: 31 Jan 2009
Last updated on STN: 31 Jan 2009

L61 ANSWER 47 OF 155 MEDLINE on STN DUPLICATE 7
TI Angiogenesis, vascular endothelial growth factor and the endometrium.
SO Human reproduction update, (1998 Sep-Oct) Vol. 4, No. 5, pp. 509-19. Ref: 130
Journal code: 9507614. ISSN: 1355-4786.
AU Smith S K
AN 1999149849 MEDLINE

L61 ANSWER 48 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Control of the membrane sex hormone-binding globulin-receptor (SHBG-R) in MCF-7 cells: Effect of locally produced SHBG
SO Steroids (1998), 63(5/6), 282-284
CODEN: STEDAM; ISSN: 0039-128X
AU Fortunati, Nicoletta; Raineri, Mariangela; Cignetti, Alessandro; Hammond, Geoffrey L.; Frairia, Roberto
AN 1998:363284 HCAPLUS
DN 129:90586
OREF 129:18531a,18534a

L61 ANSWER 49 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Negative feedback control of the spermatogenic progression by testicular estrogen synthesis: insights from the shark testis model
SO APMIS (1998), 106(1), 252-258
CODEN: APMSEL; ISSN: 0903-4641
AU Betka, Marlies; Callard, Gloria V.
AN 1998:205623 HCAPLUS
DN 128:280989
OREF 128:55585a

L61 ANSWER 50 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Physiological changes in extracellular sodium directly control human proximal tubule growth and transport
SO Pfluegers Archiv (1998), 435(2), 211-218
CODEN: PFLABK; ISSN: 0031-6768
AU Johnson, David W.; Saunders, Heather J.; Poronnik, Philip; Cook, David I.; Field, Michael J.; Pollock, Carol A.
AN 1997:753988 HCAPLUS
DN 128:152301
OREF 128:29957a,29960a

L61 ANSWER 51 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of tetrandrine on proliferation of vascular smooth muscle cells and expression on oncogenes
SO Zhongguo Zuzhi Huaxue Yu Xibao Huaxue Zazhi (1998), 7(2), 198-202
CODEN: ZZXZFZ; ISSN: 1004-1850

AU Xiong, Yili; Zhang, Min; Yao, Weixing
AN 1998:610422 HCAPLUS
DN 130:20389

L61 ANSWER 52 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Control of vascular smooth muscle cell growth in fowl
SO General and Comparative Endocrinology (1998), 112(1), 115-128
CODEN: GCENA5; ISSN: 0016-6480
AU Shimada, Toshio; Fabian, Matthew; Yan, Hong-Q.; Nishimura, Hiroko
AN 1998:665243 HCAPLUS
DN 130:12547

L61 ANSWER 53 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI A cell-based potency assay for insulin-like growth factor-I
SO BIOLOGICALS, (MAR 1998) Vol. 26, No. 1, pp. 61-68.
ISSN: 1045-1056.
AU Gazzano-Santoro H (Reprint); Chen A; Mukku V
AN 1998:457925 SCISEARCH

L61 ANSWER 54 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Genetic vectors comprising a gene of interest and a tetracycline-controlled activator gene and uses in tetracycline-regulated gene therapy or immunization systems
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
IN Hobart, Peter M.; Liang, Xiaowu
AN 1997:650465 HCAPLUS
DN 127:304110
OREF 127:59343a,59346a

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9735992	A1	19971002	WO 1997-US4187	19970317
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5891718	A	19990406	US 1996-622956	19960327

L61 ANSWER 55 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
SO U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 924,476, abandoned.
CODEN: USXXAM
IN Dunn, James M.
AN 1997:705881 HCAPLUS
DN 127:362623
OREF 127:70893a,70896a

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5681581	A	19971028	US 1995-379472	19950327
WO 9403471	A1	19940217	WO 1993-US7308	19930804
W: AU, CA, FI, JP, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

L61 ANSWER 56 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein
SO Blood (1997), 89(11), 4092-4099
CODEN: BLOOAW; ISSN: 0006-4971
AU Yamauchi, Akira; Bloom, Eda T.
AN 1997:344918 HCAPLUS
DN 127:63646

OREF 127:12153a,12156a

L61 ANSWER 57 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN DUPLICATE 8
TI Application of microautoradiography to the study of substrate uptake by filamentous microorganisms in activated sludge
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY, (SEP 1997) Vol. 63, No. 9, pp. 3662-3668.
ISSN: 0099-2240.
AU Andreasen K (Reprint); Nielsen P H
AN 1997:682896 SCISEARCH

L61 ANSWER 58 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts
SO Oncogene (1997), 15(22), 2743-2747
CODEN: ONCNES; ISSN: 0950-9232
AU Dietrich, Cornelia; Wallenfang, Katja; Oesch, Franz; Wieser, Raimund
AN 1997:801430 HCAPLUS
DN 128:113406
OREF 128:22201a,22204a

L61 ANSWER 59 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Role of prostaglandin H synthase-2-mediated conversion of arachidonic acid in controlling 3T6 fibroblast growth
SO American Journal of Physiology (1997), 273(5, Pt. 1), C1466-C1471
CODEN: AJPHAP; ISSN: 0002-9513
AU Martinez, Javier; Sanchez, Teresa; Moreno, Juan J.
AN 1997:755407 HCAPLUS
DN 128:44167
OREF 128:8547a,8550a

L61 ANSWER 60 OF 155 BIOTECHNO COPYRIGHT 2009 Elsevier Science B.V. on STN
TI Cyclo-saligenyl-2',3'-dideoxy-2',3' didehydroythymidinemonophosphate (cyclosal-d4TMP) - A new pro-nucleotide approach
SO Nucleosides and Nucleotides, (1997), 16/7-9 (1303-1306), 2 reference(s)
CODEN: NUNUD5 ISSN: 0732-8311
AU Meier C.; Lorey M.; De Clercq E.; Balzarini J.
AN 1997:27494468 BIOTECHNO

L61 ANSWER 61 OF 155 BIOTECHNO COPYRIGHT 2009 Elsevier Science B.V. on STN
TI Cyclo-saligenyl-3'-azido-2',3'-dideoxythymidinemonophosphate (CycloSal-AZTMP) - A new pro-nucleotide approach
SO Nucleosides and Nucleotides, (1997), 16/5-6 (793-796), 8 reference(s)
CODEN: NUNUD5 ISSN: 0732-8311
AU Meier C.; De Clercq E.; Balzarini J.
AN 1997:27330216 BIOTECHNO

L61 ANSWER 62 OF 155 MEDLINE on STN DUPLICATE 9
TI Effects of 1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino) propane hydrochloride on proliferation of vascular smooth muscle cells and PDGF-B, bFGF, c-sis, c-myc in spontaneously hypertensive rat.
SO Yao xue xue bao = Acta pharmaceutica Sinica, (1997 Sep) Vol. 32, No. 9, pp. 658-62.
Journal code: 21710340R. ISSN: 0513-4870.
AU Xiong Y L; Qian J Q
AN 2001549850 MEDLINE

L61 ANSWER 63 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of 1-(2,6-dimethylphenoxy)-2-(3,4- dimethoxyphenylethylamino) propane hydrochloride on proliferation of vascular smooth muscle cells and PDGF-B, bFGF, c-sis, c-myc in experimental hypertensive rats

SO Zhongguo Yaoxue Zazhi (Beijing) (1997), 32(9), 529-532
CODEN: ZYZAEU; ISSN: 1001-2494
AU Xiong, Yili; Qian, Jiaqing
AN 1998:368173 HCAPLUS
DN 129:184022
OREF 129:37213a,37216a

L61 ANSWER 64 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of 1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane hydrochloride on proliferation of vascular smooth muscle cells and heat stress protein and P53
SO Zhongguo Yiyuan Yaoxue Zazhi (1997), 17(10), 437-439
CODEN: ZYYAEP; ISSN: 1001-5213
AU Xiong, Yili; Qian, Jiaqing; Wang, Hongwei
AN 1998:156645 HCAPLUS
DN 128:289953
OREF 128:57267a,57270a

L61 ANSWER 65 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of captopril on proliferation of vascular smooth muscle cells and expression of oncogenes c-myc, c-fos, c-sis and antioncogene p53 in spontaneously hypertensive rats
SO Zhongguo Yaolixue Tongbao (1997), 13(5), 413-415
CODEN: ZYTOE8; ISSN: 1001-1978
AU Xiong, Yili; Niu, Lili; Zhang, Min
AN 1998:385641 HCAPLUS
DN 129:211428
OREF 129:42771a,42774a

L61 ANSWER 66 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of DDPH on proliferation of vascular smooth muscle cells and expression of oncogenes c-myc, c-fos, c-sis and antioncogene P53 in spontaneously hypertensive rat
SO Tongji Yike Daxue Xuebao (1997), 26(4), 249-252
CODEN: TYDXEP; ISSN: 0258-2090
AU Xiong, Yili; Wang, Hongwei; Qian, Jiaqing
AN 1998:540391 HCAPLUS
DN 129:325878
OREF 129:66287a,66290a

L61 ANSWER 67 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of tributyltin on Ca2+ homeostasis and mechanisms controlling cell cycling in sea urchin eggs
SO Aquatic Toxicology (1997), 38(4), 225-239
CODEN: AQTODG; ISSN: 0166-445X
AU Girard, Jean-Pierre; Ferrua, Corine; Pesando, Danielle
AN 1997:401935 HCAPLUS
DN 127:77061
OREF 127:14629a,14632a

L61 ANSWER 68 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of 1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane hydrochloride on endothelin-stimulated proliferation of vascular smooth muscle cells and expression of oncogenes
SO Zhongguo Yaolixue Yu Dulixue Zazhi (1997), 11(3), 187-189
CODEN: ZYYZEW; ISSN: 1000-3002
AU Xiong, Yili; Qian, Jiaqing; Wang, Hongwei
AN 1998:242330 HCAPLUS
DN 129:90126
OREF 129:18407a,18410a

L61 ANSWER 69 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Sexually dimorphic neuron addition to an avian song-control region is not accounted for by sex differences in cell death
SO Journal of Neurobiology (1997), 33(1), 61-71
CODEN: JNEUBZ; ISSN: 0022-3034
AU Burek, M. J.; Nordeen, K. W.; Nordeen, E. J.
AN 1997:466944 HCAPLUS
DN 127:119737
OREF 127:23033a,23036a

L61 ANSWER 70 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Fully differentiated human cell lines containing immortalizing agent; differentiation and immortalization with e.g. an SV40 virus T-antigen gene and a safety gene, e.g. thymidine-kinase or cytosine-deaminase gene, for drug testing or transplantation
AU Stringer B M J
AN 1996-08196 BIOTECHDS
PI GB 2294946 15 May 1996

L61 ANSWER 71 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI A cubic-phase oral drug delivery system for controlled release of AG337
SO Drug Development and Industrial Pharmacy (1996), 22(7), 603-608
CODEN: DDIPD8; ISSN: 0363-9045
AU Longer, Mark; Tyle, Praveen; Mauger, John W.
AN 1996:402803 HCAPLUS
DN 125:67497
OREF 125:12743a,12746a

L61 ANSWER 72 OF 155 LIFESCI COPYRIGHT 2009 CSA on STN
TI Inhibitors of infectious pancreatic necrosis virus (IPNV) replication
SO ANTIVIRAL RES., (1996) vol. 29, no. 2-3, pp. 309-312.
ISSN: 0166-3542.
AU Jashes, M.; Gonzalez, M.; Lopez-Lastra, M.; Clercq, E.D.; Sandino, A.
AN 96:64317 LIFESCI

L61 ANSWER 73 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Controlling regioselectivity in enzyme-catalyzed acylation of polyhydroxyl compounds
SO Annals of the New York Academy of Sciences (1996), 799(Enzyme Engineering XIII), 226-230
CODEN: ANYAA9; ISSN: 0077-8923
AU Rich, Joseph O.; Dordick, Jonathan S.
AN 1997:103444 HCAPLUS
DN 126:183021
OREF 126:35269a,35272a

L61 ANSWER 74 OF 155 MEDLINE on STN DUPLICATE 10
TI [Gene transfer and radiotherapy].
Transfert genique et radiotherapie.
SO Bulletin du cancer, (1996 Feb) Vol. 83, No. 2, pp. 107-13. Ref: 43
Journal code: 0072416. ISSN: 0007-4551.
AU Bourhis J; Cosset J M; Dionet C; Kreitmann T; Girinski T; Dubray B; Magdalenat H; Eschwege F; Verrelle P
AN 1996256113 MEDLINE

L61 ANSWER 75 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN DUPLICATE 11
TI Labeling of thymine with (99m)technetium: A suggestion of a chemical model
SO ARQUIVOS DE BIOLOGIA E TECNOLOGIA, (1996) Vol. 39, No. 1, pp. 69-74.
ISSN: 0365-0979.
AU Gutfilen B (Reprint); Ribeiro B L A; Mattos M F; daSilva C R; Bernardo M
AN 1996:547481 SCISEARCH

L61 ANSWER 76 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI The exit from G0 into the cell cycle requires and is controlled by sarco(endo)plasmic reticulum Ca2+ pump
SO Archives of Biochemistry and Biophysics (1996), 329(1), 65-72
CODEN: ABBIA4; ISSN: 0003-9861
AU Cheng, Guangmao; Liu, Bei-Fang; Yu, Yingjie; Diglio, Clement; Kuo, Tuan H.
AN 1996:255680 HCAPLUS
DN 124:282216
OREF 124:52087a,52090a

L61 ANSWER 77 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Tyrosine 807 of the v-Fms oncogene product controls cell morphology and association with p120RasGAP
SO Journal of Virology (1995), 69(10), 6010-20
CODEN: JOVIAM; ISSN: 0022-538X
AU Trouliaris, Sylvia; Smola, Ute; Chang, Jin-Hong; Parsons, Sarah J.; Niemann, Heiner; Tamura, Teruko
AN 1995:812541 HCAPLUS
DN 123:224681
OREF 123:40027a,40030a

L61 ANSWER 78 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Regulation of mouse thymidylate synthase gene expression in growth-stimulated cells: upstream S phase control elements are indistinguishable from the essential promoter elements
SO Nucleic Acids Research (1995), 23(22), 4649-56
CODEN: NARHAD; ISSN: 0305-1048
AU Ash, John; Liao, Wen-Chieh; Ke, Yunbo; Johnson, Lee F.
AN 1995:1007242 HCAPLUS
DN 124:79612
OREF 124:14761a,14764a

L61 ANSWER 79 OF 155 MEDLINE on STN DUPLICATE 12
TI Controlled release of platelet-derived growth factor using ethylene vinyl acetate copolymer (EVAc) coated on stainless-steel wires.
SO Biomaterials, (1995 Nov) Vol. 16, No. 17, pp. 1319-25.
Journal code: 8100316. ISSN: 0142-9612.
AU Walsh W R; Kim H D; Jong Y S; Valentini R F
AN 1996126604 MEDLINE

L61 ANSWER 80 OF 155 MEDLINE on STN DUPLICATE 13
TI Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.
SO Cancer research, (1995 Feb 15) Vol. 55, No. 4, pp. 853-61.
Journal code: 2984705R. ISSN: 0008-5472.
AU Ponzoni M; Bocca P; Chiesa V; Decensi A; Pistoia V; Raffaghello L; Rozzo C; Montaldo P G
AN 1995153678 MEDLINE

L61 ANSWER 81 OF 155 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on STN
AN 1995041702 ESBIOBASE
TI Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation
AU Ponzoni, Mirco; Bocca, Paola; Chisea, Valeria; Pistoia, Vito; Raffaghello, Lizzya; Rozzo, Carla; Montaldo, Paolo Giuseppe; Decensi, Andrea
CS Ponzoni, Mirco; Bocca, Paola; Chisea, Valeria; Pistoia, Vito; Raffaghello, Lizzya; Rozzo, Carla; Montaldo, Paolo Giuseppe (Oncology Research Laboratory, G. Gaslini Children's Hospital, Largo G. Gaslini 5, Genoa 16148 (IT)); Decensi, Andrea (Department of Medical Oncology II,

National Cancer Institute, Genoa 16132 (IT))
SO Cancer Research (15 Feb 1995) Volume 55, Number 4, pp. 853-861, 61 refs.
CODEN: CNREA8 ISSN: 0008-5472
CY United States of America
DT Journal; Article
LA English
SL English
ED Entered STN: 30 Jan 2009
Last updated on STN: 30 Jan 2009

L61 ANSWER 82 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Liquid-culture pH, temperature, and carbon (not nitrogen) source regulate phenazine productivity of the take-all biocontrol agent Pseudomonas fluorescens 2-79;
phenazine-1-carboxylic acid production; pH, temperature and C-source effect
SO Appl.Microbiol.Biotechnol.; (1995) 43, 5, 794-800
CODEN: EJABDD ISSN: 0175-7598
AU Slininger P J; Shea-Wilbur M A
AN 1995-15215 BIOTECHDS

L61 ANSWER 83 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Fermentative production of methionine by 5-bromouracil-resistant mutants of Escherichia coli K-12;
methionine over production by 5-bromourail-resistant Escherichia coli mutant
SO Med.Sci.Res.; (1995) 48, 4, 775
CODEN: MSCREJ ISSN: 0269-8951
AU Chattapadhyay M K; Sngupta D; Sengupta S
AN 1996-00377 BIOTECHDS

L61 ANSWER 84 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Thymine labeled with technetium-99m: Radiochemical control
SO Synthesis and Applications of Isotopically Labelled Compounds 1994, Proceedings of the International Symposium, 5th, Strasbourg, June 20-24, 1994 (1995), Meeting Date 1994, 395-8. Editor(s): Allen, John; Voges, Rolf. Publisher: Wiley, Chichester, UK.
CODEN: 61UMAF
AU Gutfilen, B.; Ribeiro, B. A.; Bernardo-Filho, M.
AN 1995:911362 HCAPLUS
DN 124:24902
OREF 124:4699a,4702a

L61 ANSWER 85 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Epithelial rat thyroid cell clones, escaping from transforming growth factor β negative growth control, are still inhibited by this factor in the ability to trap iodide
SO Cell Growth & Differentiation (1995), 6(3), 281-90
CODEN: CGDIE7; ISSN: 1044-9523
AU Coppa, Anna; Mincione, Gabriella; Mammarella, Sandra; Ranieri, Annalisa; Colletta, Giulia
AN 1995:425403 HCAPLUS
DN 122:179337
OREF 122:32701a,32704a

L61 ANSWER 86 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Estrogen promotes neuron addition to an avian song-control nucleus by regulating post-mitotic events
SO Developmental Brain Research (1995), 85(2), 220-4
CODEN: DBRRDB; ISSN: 0165-3806
AU Burek, M. J.; Nordeen, K. W.; Nordeen, E. J.
AN 1995:520994 HCAPLUS

DN 122:261620
OREF 122:47657a,47660a

L61 ANSWER 87 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Cell synchronization as a basis for investigating control of proliferation in mammalian cells
SO Cell Growth and Apoptosis (1995), 193-203. Editor(s): Studzinski, George P. Publisher: IRL Press, Oxford, UK.
CODEN: 62WZA3
AU Stein, Gary S.; Stein, Janet L.; Lian, Jane B.; Last, T. J.; Owen, Thomas; McCabe, Laura
AN 1996:342931 HCAPLUS
DN 125:52945
OREF 125:10081a,10084a

L61 ANSWER 88 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI In vivo studies of the control of DNA synthesis in the rat adrenal cortex and medulla
SO Endocrine Research (1995), 21(1 & 2), 91-102
CODEN: ENRSE8; ISSN: 0743-5800
AU McEwan, Pauline E.; Lindop, George B. M.; Kenyon, Christopher J.
AN 1995:672502 HCAPLUS
DN 123:194657
OREF 123:34597a,34600a

L61 ANSWER 89 OF 155 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Oral compsn. for controlling dental plaque, etc. - containing purine or pyrimidine skeleton cpd. bound to water insol. carrier
PI JP 06287122 A 19941011 (199445)* JA 6[0]
JP 3039831 B2 20000508 (200027) JA 5
IN ADACHI S; SUIDOU H

L61 ANSWER 90 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI heparan sulfate proteoglycan and control of cell proliferation: enhanced synthesis induced by phorbol ester (PMA) during G1-phase
SO Brazilian Journal of Medical and Biological Research (1994), 27(9), 2185-90
CODEN: BJMRDK; ISSN: 0100-879X
AU Porcionatto, M.A.; Pinto, C.R.M.; Dietrich, C.P.; Nader, H.B.
AN 1995:139158 HCAPLUS
DN 122:28845
OREF 122:5673a,5676a

L61 ANSWER 91 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI PROGNOSTIC FACTORS IN MYELOMA - WHAT THEY TELL US ABOUT THE PATHOPHYSIOLOGY OF THE DISEASE
SO LEUKEMIA & LYMPHOMA, (NOV 1994) Vol. 15, No. 5-6, pp. 375-381.
ISSN: 1042-8194.
AU JOSHUA D E (Reprint); BROWN R D; GIBSON J
AN 1994:739564 SCISEARCH

L61 ANSWER 92 OF 155 NTIS COPYRIGHT 2009 NTIS on STN
TI Moeglichkeiten des biologischen Containments bei der gezielten Freisetzung von gentechnisch veraenderten Organismen. (Possibilities of biological containment for the deliberate release of genetically engineered organisms).
NR TIB/A95-03492/XAB; UBA-FB--94-124
117p; Jul 1993
PD Jul 1993
AU Reiting, R.H.; Kiani, E.; Schmidt, F.R.J.
AN 1995(19):08779 NTIS

L61 ANSWER 93 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Recombinant Heliothis armigera entomopox virus and recombinant nuclear-polyhedrosis virus;
application as a biodegradable agent and in recombinant protein e.g. interferon-alpha production
AN 1994-02697 BIOTECHDS
PI WO 9325666 23 Dec 1993

L61 ANSWER 94 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Posttranscriptional control of thymidine kinase messenger RNA accumulation in cells released from G0-G1 phase blocks
SO Cell Growth & Differentiation (1993), 4(5), 421-30
CODEN: CGDIE7; ISSN: 1044-9523
AU Gudas, Jean M.; Fridovich-Keil, Judith L.; Pardee, Arthur B.
AN 1993:646631 HCAPLUS
DN 119:246631
OREF 119:43939a,43942a

L61 ANSWER 95 OF 155 BIOTECHNO COPYRIGHT 2009 Elsevier Science B.V. on STN
TI A mutation (Trp.sup.1.sup.1.sup.9.sup.3 → Leu.sup.1.sup.1.sup.9.sup.3) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance
SO Diabetologia, (1993), 36/5 (414-422)
CODEN: DBTGAJ ISSN: 0012-186X
AU Iwanishi M.; Haruta T.; Takata Y.; Ishibashi O.; Sasaoka T.; Egawa K.; Imamura T.; Naitou K.; Itazu T.; Kobayashi M.
AN 1993:23124045 BIOTECHNO

L61 ANSWER 96 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Transcriptional control of the PTH gene: Negative calcium-responsive element
SO International Congress, Symposium and Seminar Series (1993), Volume Date 1992, 3(PROGRESS IN ENDOCRINOLOGY), 407-10
CODEN: ICGSEM; ISSN: 0969-2622
AU Okazaki, T.; Igarashi, T.; Nishishita, T.; Chung, U.; Ogata, E.
AN 1995:135325 HCAPLUS
DN 122:125106
OREF 122:23199a,23202a

L61 ANSWER 97 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI VARIABILITY OF DISSOLVED ORGANIC-CARBON IN SEDIMENTS OF A SEAGRASS BED AND AN UNVEGETATED AREA WITHIN AN ESTUARY IN SOUTHERN TEXAS
SO ESTUARIES, (SEP 1993) Vol. 16, No. 3A, pp. 391-404.
ISSN: 0160-8347.
AU KOEPFLER E T (Reprint); BENNER R; MONTAGNA P A
AN 1993:748805 SCISEARCH

L61 ANSWER 98 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Inorganic nutrient and carbon controlled bacterioplankton growth in the Baltic Sea
SO Estuarine, Coastal and Shelf Science (1993), 37(3), 271-85
CODEN: ECSSD3; ISSN: 0272-7714
AU Kuparinen, Jorma; Heinanen, Anne
AN 1994:199870 HCAPLUS
DN 120:199870
OREF 120:35225a,35228a

L61 ANSWER 99 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI n-3 PUFA and α-tocopherol control of tumor cell proliferation
SO Molecular Aspects of Medicine (1993), 14(3), 247-52

CODEN: MAMED5; ISSN: 0098-2997
AU Bartoli, G. M.; Palozza, P.; Marra, G.; Armelao, F.; Franceschelli, P.; Luberto, C.; Sgarlata, E.; Piccioni, E.; Anti, M.
AN 1994:209 HCAPLUS
DN 120:209
OREF 120:47a,50a

L61 ANSWER 100 OF 155 MEDLINE on STN DUPLICATE 14
TI DNA flow cytometry measurements as surrogate endpoints in chemoprevention trials: clinical, biological, and quality control considerations.
SO Journal of cellular biochemistry. Supplement, (1993) Vol. 17G, pp. 212-8. Ref: 28
Journal code: 8207539. ISSN: 0733-1959.
AU Dressler L G
AN 1994276616 MEDLINE

L61 ANSWER 101 OF 155 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI A myxoma virus intergenic transient dominant selection vector.
SO Journal of General Virology, (1992) Vol. 73, No. 12, pp. 3241-3245.
CODEN: JGVIAY. ISSN: 0022-1317.
AU Jackson, Ronald J.; Bults, Harold G.
AN 1993:140414 BIOSIS

L61 ANSWER 102 OF 155 MEDLINE on STN DUPLICATE 15
TI Biocompatibility of lipid microcylinders: effect on cell growth and antigen presentation in culture.
SO Biomaterials, (1992) Vol. 13, No. 15, pp. 1085-92.
Journal code: 8100316. ISSN: 0142-9612.
AU Rudolph A S; Stilwell G; Cliff R O; Kahn B; Spargo B J; Rollwagen F; Monroy R L
AN 1993152704 MEDLINE

L61 ANSWER 103 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Specialized host-vector systems for the engineering of Pseudomonas st rains destined for environmental release;
selectable marker systems, plasmid and transposon vector construction and biological containment of genetically engineered microorganism r eleased to the environment (conference paper)
SO Pseudomonas Mol.Biol.Biotechnol.; (1992) 415-28
AU de Lorenzo V; Timmis K N
AN 1993-11340 BIOTECHDS

L61 ANSWER 104 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Genetically modified plant-microbe interacting strains for potential release into the rhizosphere;
Pseudomonas spp. biological control agent genetically engineered microorganism release to the environment; siderophore and fungicide over-production and vector construction (conference paper)
SO Pseudomonas Mol.Biol.Biotechnol.; (1992) 408-14
AU Dowling D N; Boesten B; O'Sullivan D J; Stephens P; Morris J; O'Gara F
AN 1993-11034 BIOTECHDS

L61 ANSWER 105 OF 155 MEDLINE on STN DUPLICATE 16
TI Embryonic brain-derived heparan sulfate inhibits cellular membrane binding and biological activity of basic fibroblast growth factor.
SO Brain research. Developmental brain research, (1992 Aug 21) Vol. 68, No. 2, pp. 247-53.
Journal code: 8908639. ISSN: 0165-3806.

AU Hondermarck H; Deudon E; Boilly B
AN 1993008929 MEDLINE

L61 ANSWER 106 OF 155 MEDLINE on STN DUPLICATE 17
TI Growth inhibition of human colorectal carcinoma cell lines by tumor necrosis factor-alpha correlates with reduced activity of pp60c-src.
SO Journal of immunotherapy : official journal of the Society for Biological Therapy, (1992 Apr) Vol. 11, No. 3, pp. 159-68.
Journal code: 9102704. ISSN: 1053-8550.
AU Novotny-Smith C L; Gallick G E
AN 1992385447 MEDLINE

L61 ANSWER 107 OF 155 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Nucleic acid sequencing - using tetra:methyl-rhodamine, rhodamine X, rhodamine 6G and rhodamine 110 to label polynucleotide classes
PI WO 9105060 A 19910418 (199118)* EN
RW: AT BE CH DE DK ES FR GB IT LU NL SE
W: JP
EP 496749 A1 19920805 (199232) EN 28[0]
R: AT BE CH DE DK ES FR GB IT LI LU NL SE
JP 05502371 W 19930428 (199322) JA 9
US 5366860 A 19941122 (199501) EN 8[0]
WO 9105060 A3 19910516 (199508) EN
EP 496749 A4 19930616 (199526) EN
EP 496749 B1 19951206 (199602) EN 27[0]
R: AT BE CH DE DK ES FR GB IT LI LU NL SE
DE 69024061 E 19960118 (199608) DE
JP 2649102 B2 19970903 (199740) JA 10[0]
IN BERGOT B J; BERGOT J B; CHAKERIAN V; CONNELL C R; EADIE J; EADIE J S; FUNG S; HERSHEY D N; HERSHEY N D; JALAL M A F; LEE L G; MENCHEN S M; ROBESON D J; SIMPSON R B; WOO S L

L61 ANSWER 108 OF 155 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN DUPLICATE 18
TI THE ROLE OF INTERTIDAL MUDBANKS IN THE DIAGENESIS AND EXPORT OF DISSOLVED AND PARTICULATE MATERIALS FROM THE FLY-DELTA, PAPUA-NEW-GUINEA
SO JOURNAL OF EXPERIMENTAL MARINE BIOLOGY AND ECOLOGY, (1991) Vol. 149, No. 1, pp. 81-107.
ISSN: 0022-0981.
AU ALONGI D M (Reprint)
AN 1991:403726 SCISEARCH

L61 ANSWER 109 OF 155 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Semi-plastic products reduction from poly-inosinic acid - and complementary nucleotide, useful as stable interferon inducers and killer cell activators
PI DD 275692 A 19900131 (199028)* DE [4]
DD 275692 C 19901024 (199113) DE
IN GOTTSETEIN H; HOFFMANN S; MEISTER S; WASCHKE K; WITKOWSKI W

L61 ANSWER 110 OF 155 MEDLINE on STN
TI Bombesin receptor antagonists [corrected]. 1. Analogues with deleted, inverted or substituted amino acid residues.
SO Farmaco (Societa chimica italiana : 1989), (1990 Dec) Vol. 45, No. 12, pp. 1251-63.
Journal code: 8912641. ISSN: 0014-827X.
AU De Castiglione R; Gozzini L; Mena R; Brugnolotti M; Ciomei M; Molinari I; Comoglio P M; Gaudino G
AN 1991214483 MEDLINE

L61 ANSWER 111 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Construction of direct selection vectors for use in Bacillus sphaericus

and Bacillus subtilis;
vector plasmid pAFE450 construction (conference abstract)
SO Abstr.Annu.Meet.Am.Soc.Microbiol.; (1990) 90 Meet., 181
AU Ehrhardt A F; Burke Jr W F
AN 1990-12412 BIOTECHDS

L61 ANSWER 112 OF 155 MEDLINE on STN
TI DNA dynamics in aqueous solution: opening the double helix.
SO The international journal of supercomputer applications, (1990 Fall) Vol. 4, No. 3, pp. 81-96.
Journal code: 9882953. ISSN: 0890-2720.
(Investigators: MacElroy R D, ARC) Report No.: NASA-00014087.
AU Pohorille A; Ross W S; Tinoco I Jr
AN 2001656913 MEDLINE

L61 ANSWER 113 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI An expression vector for animal cell transformation;
plasmid pSV21FN(r)-beta application in human recombinant interferon-beta production in Chinese hamster ovary (CHO) cell culture
AN 1989-14210 BIOTECHDS
PI JP 01196296 8 Aug 1989

L61 ANSWER 114 OF 155 LIFESCI COPYRIGHT 2009 CSA on STN DUPLICATE 19
TI A pyrimidine auxotroph of Sclerotinia sclerotiorum for use in biological weed control.
SO J. GEN. MICROBIOL., (1989) vol. 135, no. 7, pp. 2085-2091.
AU Miller, R.V.; Ford, E.J.; Zidack, N.J.; Sands, D.C.
AN 89:51107 LIFESCI

L61 ANSWER 115 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of 2,4-dichlorophenoxyacetic acid (2,4-D) and α-naphthalene acetic acid (NAA) on the control of the cell cycle of Daphne odora stem callus
SO Cell Biology International Reports (1989), 13(11), 971-3
CODEN: CBRPDS; ISSN: 0309-1651
AU Zhou, Juhua; Liang, Haiman
AN 1990:73959 HCAPLUS
DN 112:73959
OREF 112:12575a,12578a

L61 ANSWER 116 OF 155 MEDLINE on STN
TI Nonterminally differentiated cells express decreased growth factor responsiveness.
SO Journal of cellular physiology, (1989 Apr) Vol. 139, No. 1, pp. 68-75.
Journal code: 0050222. ISSN: 0021-9541.
AU Hoerl B J; Scott R E
AN 1989214360 MEDLINE

L61 ANSWER 117 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Negative control elements and cAMP responsive sequences in the tissue-specific expression of mouse renin genes
SO Proceedings of the National Academy of Sciences of the United States of America (1989), 86(1), 56-9
CODEN: PNASA6; ISSN: 0027-8424
AU Nakamura, Norifumi; Burt, David W.; Paul, Martin; Dzau, Victor J.
AN 1989:129625 HCAPLUS
DN 110:129625
OREF 110:21275a,21278a

L61 ANSWER 118 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI The cell cycle and restriction point control
SO Bristol-Myers Cancer Symposia (1989), 10(Regul. Proliferation Differ.

Norm. Neoplast. Cells), 3-20
CODEN: BCSYDM; ISSN: 0197-8756
AU Gudas, Jean M.; Knight, Glenn B.; Pardee, Arthur B.
AN 1990:456175 HCAPLUS
DN 113:56175
OREF 113:9445a,9448a

L61 ANSWER 119 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Sterol regulatory elements and their use in control of gene expression and in drug screening assays
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
IN Brown, Michael S.; Goldstein, Joseph L.; Russell, David W.; Sudhof, Thomas C.
AN 1989:402170 HCAPLUS
DN 111:2170
OREF 111:427a,430a

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 8807579	A1	19881006	WO 1988-US1095	19880330
W: AT, AU, BB, BG, BR, CH, DE, DK, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU				
RW: AT, BE, BJ, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 4935363	A	19900619	US 1987-33302	19870330
AU 8815968	A	19881102	AU 1988-15968	19880330
AU 608841	B2	19910418		
EP 353246	A1	19900207	EP 1988-903701	19880330
EP 353246	B1	19930929		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 02502694	T	19900830	JP 1988-503433	19880330
CA 1300533	C	19920512	CA 1988-563000	19880330
AT 95241	T	19931015	AT 1988-903701	19880330

L61 ANSWER 120 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI A DNA segment controlling metal-regulated expression of the Drosophila melanogaster metallothionein gene Mtn
SO Molecular and Cellular Biology (1987), 7(5), 1710-15
CODEN: MCEBD4; ISSN: 0270-7306
AU Otto, Edward; Allen, James M.; Young, Julie E.; Palmiter, Richard D.; Maroni, Gustavo
AN 1987:401846 HCAPLUS
DN 107:1846
OREF 107:347a,350a

L61 ANSWER 121 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Analysis of human lymphoblast mutation assays by using historical negative control data bases
SO Environmental and Molecular Mutagenesis (1987), 10(1), 35-60
CODEN: EMMUEG; ISSN: 0893-6692
AU Penman, Bruce W.; Crespi, Charles L.
AN 1987:548669 HCAPLUS
DN 107:148669
OREF 107:23833a,23836a

L61 ANSWER 122 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI New promoter having 5'-flanking region replaced;
for enhanced transcriptional activity without impaired function of original trp and tac promoters
AN 1985-11399 BIOTECHDS
PI EP 152613 28 Aug 1985

L61 ANSWER 123 OF 155 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI Glucocorticoid-induced modulation of insulin-stimulated DNA synthesis: Differential responsiveness in cell cultures derived from donors of different ages.
SO Gerontology, (1985) Vol. 31, No. 2, pp. 65-75.
ISSN: 0304-324X CODEN: GERNDJ
AU Germinario, R.J.; McQuillan, A.
AN 1985140204 EMBASE

L61 ANSWER 124 OF 155 LIFESCI COPYRIGHT 2009 CSA on STN
TI Comparative action of the solubilized crystals of H-14 and H-1 serotypes of Bacillus thuringiensis on Aedes aegypti cell cultures.
Action comparee des cristaux solubilises des serotypes H-14 et H-1 de Bacillus thuringiensis sur des cultures de cellules de Aedes aegypti
SO ANN. MICROBIOL., (1984) vol. 135, no. 3, pp. 473-484.
AU Laurent, P.; Charles, J.-F.
AN 84:27782 LIFESCI

L61 ANSWER 125 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Glucagon control of carcinogenesis
SO Endocrinology (1983), 113(2), 527-34
CODEN: ENDOAO; ISSN: 0013-7227
AU Lupulescu, A.
AN 1983:482891 HCAPLUS
DN 99:82891
OREF 99:12693a,12696a

L61 ANSWER 126 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Studies of the simultaneous reversion for thy dra and drm genes; selection of the biological control agent Bacillus thuringiensis var. galleriae mutants with respect to thymine requirement and thymidine sensitivity
SO Genetika(Moscow); (1983) 19, 3, 406-15
CODEN: GNKAA5
AU Grigorieva T M; Azizbekyan R R
AN 1983-03778 BIOTECHDS

L61 ANSWER 127 OF 155 MEDLINE on STN DUPLICATE 20
TI The cytotoxic activity of heterologous anti-L-1210 antibodies conjugated with quinones.
SO Archivum immunologiae et therapiae experimentalis, (1983) Vol. 31, No. 1, pp. 99-106.
Journal code: 0114365. ISSN: 0004-069X.
AU Boratynski J; Syper L
AN 1983307880 MEDLINE

L61 ANSWER 128 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Naturally occurring antibiotic resistance in Bacillus sphaericus and Bacillus licheniformis; potential application of Bac. sphaericus mosquito larvicidal activity as biological control agent
SO Curr.Microbiol.; (1983) 9, 2, 69-72
CODEN: CUMIDD
AU Burke W F Jr; McDonald K O
AN 1983-09933 BIOTECHDS

L61 ANSWER 129 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Nucleotide sequence of DNA controlling expression of genes for maltosaccharide utilization in Streptococcus pneumoniae
SO Gene (1982), 20(3), 359-66
CODEN: GENED6; ISSN: 0378-1119

AU Stassi, Diane L.; Dunn, John J.; Lacks, Sanford A.
AN 1983:120490 HCAPLUS
DN 98:120490
OREF 98:18265a,18268a

L61 ANSWER 130 OF 155 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI Small cell carcinoma of the lung.
SO Cancer Treatment Reviews, (1982) Vol. 9, No. 3, pp. 237-258.
ISSN: 0305-7372 CODEN: CTREDJ
AU Comis, R.L.
AN 1983089813 EMBASE

L61 ANSWER 131 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Materials for metal pollution control: bioinorganic study of some mercury complexes
SO Journal of Environmental Sciences (Mount Prospect, Illinois) (1982), 25(3), 28-31
CODEN: JEVSAG; ISSN: 0022-0906
AU Pandey, Girish Chandra
AN 1982:521480 HCAPLUS
DN 97:121480
OREF 97:20077a,20080a

L61 ANSWER 132 OF 155 MEDLINE on STN DUPLICATE 21
TI Specificity of lymphocyte stimulation in vitro by microbial preparations: importance of antigen concentration.
SO Acta pathologica et microbiologica Scandinavica. Section C, Immunology, (1981 Dec) Vol. 89, No. 6, pp. 365-71.
Journal code: 7508469. ISSN: 0304-1328.
AU Mogensen H H; Andersen V
AN 1982156184 MEDLINE

L61 ANSWER 133 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI A hormonally controlled serum factor stimulating the thymidine uptake into lectin-activated lymphocytes
SO Acta Endocrinologica (1981), 98(3), 358-63
CODEN: ACENA7; ISSN: 0001-5598
AU Thieriot-Prevost, Genevieve; Schimpff, Rose Marie
AN 1981:597962 HCAPLUS
DN 95:197962
OREF 95:32945a,32948a

L61 ANSWER 134 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI The conformation of antigenic determinants of insulin and H-2 gene control of the immune response of T lymphocytes
SO Struct. Aspects Recognit. Assem. Biol. Macromol., Proc. Aharon Katzir-Katchalsky Conf., 7th (1981), Meeting Date 1980, Volume 1, 263-79.
Editor(s): Balaban, Miriam. Publisher: Balaban Int. Sci. Serv., Rehovot, Israel.
CODEN: 46MJAD
AU Ranghino, G.; Talmon, J.; Yonath, A.; Cohen, I. R.
AN 1981:618774 HCAPLUS
DN 95:218774
OREF 95:36496h,36497a

L61 ANSWER 135 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Genetic control of anti-insulin responses is associated with activation of different T-cell sets
SO Basic Clin. Aspects Immun. Insulin, Proc., Int. Workshop (1981), Meeting Date 1980, 127-42. Editor(s): Keck, Klaus; Erb, Peter. Publisher: de Gruyter, Berlin, Fed. Rep. Ger.

CODEN: 47JQAQ
AU Abromson-Leeman, Sara; Rapp, Bonnie J.; Cantor, Harvey
AN 1982:140928 HCAPLUS
DN 96:140928
OREF 96:23149a,23152a

L61 ANSWER 136 OF 155 MEDLINE on STN DUPLICATE 22
TI A vaccine prepared from the 22 nm particles of surface hepatitis B antigen (HBsAg).
SO Journal of medical virology, (1980) Vol. 5, No. 4, pp. 331-41.
Journal code: 7705876. ISSN: 0146-6615.
AU Karelin V P; Babaeva E E; Gubenko E F; Kaulen D K; Zhdanov V M
AN 1981193641 MEDLINE

L61 ANSWER 137 OF 155 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI Lymphocyte transformation and TRH responsiveness in asymptomatic thyroiditis: Relation to thyroid hormones.
SO Journal of Endocrinological Investigation, (1979) Vol. 2, No. 1, pp. 1-4.
ISSN: 0391-4097 CODEN: JEIND7
AU Bonnyns, M.; Ermans, A.M.; Delespesse, G.
AN 1979202455 EMBASE

L61 ANSWER 138 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of cholesterol and cholesterol esters on cell function. I. Incorporation of free cholesterol and cholesterol oleate into the cell membrane and its effects on membrane fluidity, membrane fragility and DNA synthesis
SO Cell Structure and Function (1978), 3(3), 219-26
CODEN: CSFUDY; ISSN: 0386-7196
AU Naito, Mitsuko
AN 1979:165666 HCAPLUS
DN 90:165666
OREF 90:26279a,26282a

L61 ANSWER 139 OF 155 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI A SAFER ESCHERICHIA-COLI HOST FOR USE WITH EXISTING PHAGE LAMBDA VECTORS.
SO Abstracts of the Annual Meeting of the American Society for Microbiology, (1977) Vol. 77, pp. 150.
CODEN: ASMACK. ISSN: 0094-8519.
AU PEREIRA D; CURTISS R III
AN 1977:49051 BIOSIS

L61 ANSWER 140 OF 155 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI [Bioassay of somatomedin].
PROC. V. INT. CONGR. ENDOCRINOLOGY, VOL. II.
SO (1977) Vol. No. 403, pp. 150-161.
AU Phillips, L.S.; Daughaday, W.H.
AN 1978079722 EMBASE

L61 ANSWER 141 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Thymidine uptake and utilization in Escherichia coli: a new gene controlling nucleoside transport
SO Journal of Bacteriology (1976), 126(2), 814-22
CODEN: JOBAAY; ISSN: 0021-9193
AU McKeown, Michael; Kahn, Michael; Hanawalt, Philip
AN 1976:443610 HCAPLUS
DN 85:43610
OREF 85:7095a,7098a

L61 ANSWER 142 OF 155 MEDLINE on STN DUPLICATE 23
TI Induction of prophage SPO2 in Bacillus subtilis: isolation of excised prophage DNA as a covently closed circle.
SO Journal of virology, (1976 Feb) Vol. 17, No. 2, pp. 492-502.
Journal code: 0113724. ISSN: 0022-538X.
Report No.: NLM-PMC515441.
AU Arwert F; Bjursell G; Rutberg L
AN 1976146883 MEDLINE

L61 ANSWER 143 OF 155 MEDLINE on STN
TI Chemically-defined medium for growth and differentiation of mixed epithelial and connective tissues in organ culture.
SO In vitro, (1976 Jun) Vol. 12, No. 6, pp. 450-9.
Journal code: 0063733. ISSN: 0073-5655.
AU Hodges G M; Melcher A H
AN 1976259084 MEDLINE

L61 ANSWER 144 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Isolation of relaxed-control mutants of Escherichia coli K-12 which are sensitive to glucose starvation
SO Biochemical and Biophysical Research Communications (1976), 69(2), 325-32
CODEN: BBRCA9; ISSN: 0006-291X
AU Mosteller, Raymond D.; Kwan, Shing F.
AN 1976:161668 HCAPLUS
DN 84:161668
OREF 84:26239a,26242a

L61 ANSWER 145 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Dissociation of ribonucleic acid and protein synthesis in mammalian cells deprived of potassium
SO Archives of Biochemistry and Biophysics (1976), 172(1), 188-90
CODEN: ABBIA4; ISSN: 0003-9861
AU Pollack, Marc; Fisher, Harold W.
AN 1976:56948 HCAPLUS
DN 84:56948
OREF 84:9369a,9372a

L61 ANSWER 146 OF 155 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI Role of cyclic AMP in reproductive processes.
SO Fertility and Sterility, (1974) Vol. 25, No. 8, pp. 732-750.
ISSN: 0015-0282 CODEN: FESTAS
AU Menon, K.M.J.; Gunaga, K.P.
AN 1975112384 EMBASE

L61 ANSWER 147 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Repair of damage induced in ϕX174 RF[replicative form]-DNA by cobalt-60 gamma rays
SO International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine (1973), 23(6), 533-42
CODEN: IJRBA3; ISSN: 0020-7616
AU Stephan, Guenther
AN 1973:523181 HCAPLUS
DN 79:123181
OREF 79:20001a,20004a

L61 ANSWER 148 OF 155 NTIS COPYRIGHT 2009 NTIS on STN
TI Control of Degradation of Naval Materials through the Use of Biologically Active Products from the Marine Environment: The Adhesive Properties of 'Chlorella vulgaris', and the Enhancement of this Adhesion by Substances Found in Ambient Sea Water. Annual technical rept. 1 Apr 71-1 Apr 72.

NR AD-742 121/XAB; TR-2
76p; 1 Apr 1972
PD 1 Apr 1972
AU Tosteson, T. R.; Almodovar, L. R.
AN 1972(36):08403 NTIS

L61 ANSWER 149 OF 155 NTIS COPYRIGHT 2009 NTIS on STN
TI Control of Degradation of Naval Materials Through the Use of Biologically Active Products from the Marine Environment: The Adhesive Properties of 'Chlorella Vulgaris'. Annual technical rept. 1 Apr 70-1 Apr 71.
NR AD-721 114/XAB; TR-1
35p; 1 Apr 1971
PD 1 Apr 1971
AU Tosteson, T. R.; Almodovar, L. R.
AN 1971(32):07989 NTIS

L61 ANSWER 150 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Regulation of thymidine metabolism in Escherichia coli K-12: evidence that at least two operons control the degradation of thymidine
SO Journal of Bacteriology (1971), 105(3), 940-6
CODEN: JOBAAY; ISSN: 0021-9193
AU Bonney, Robert J.; Weinfeld, Herbert
AN 1971:95846 HCAPLUS
DN 74:95846
OREF 74:15555a,15558a

L61 ANSWER 151 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Lymphocyte transformation in vitro measured by tritiated thymidine uptake. I. Lymphocyte culture techniques
SO International Archives of Allergy and Applied Immunology (1970), 37(5), 506-31
CODEN: IAAAAM; ISSN: 0020-5915
AU Hughes, David; Caspary, E. A.
AN 1970:11015 HCAPLUS
DN 72:11015
OREF 72:1983a,1986a

L61 ANSWER 152 OF 155 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI The activation of DNA synthesis and cell division in rabbit lens in vitro.
SO EXPTL EYE RES, (1962) Vol. 1, No. 4, pp. 457-465.
Meeting Info.: Symposium on lens metabolism in relation to cataract, 1962.
AU HARDING, C. V.; ROTHSTEIN, H.; NEWMAN, M. B.
AN 1964:59753 BIOSIS

L61 ANSWER 153 OF 155 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN DUPLICATE 24
TI Pyrimidine nucleosides and nucleotides as growth factors for mutant strains of Neurospora.
SO JOUR BIOL CHEM, (1944) Vol. 153, No. 1, pp. 61-69.
AU Loring, Hubert S.; Pierce, John G.
AN 1944:14574 BIOSIS

L61 ANSWER 154 OF 155 NTIS COPYRIGHT 2009 NTIS on STN
TI Biocompatibility of Lipid Microcylinders: Effect on Cell Growth and Antigen Presentation in Culture. Journal article.
Reprint: Biocompatibility of Lipid Microcylinders: Effect on Cell Growth and Antigen Presentation in Culture.
NR AD-A262 206/6/XAB; NMRI-92-125
9p; 1992

AU Rudolph, A. S.; Stilwell, G.; Cliff, R. O.; Kahn, B.; Spargo, B. J.
AN 1993(19):02608 NTIS

L61 ANSWER 155 OF 155 NTIS COPYRIGHT 2009 NTIS on STN
TI Biocompatibility of Lipid Microcylinders: Effect on Cell Growth and Antigen Presentation in Culture. (Reannouncement with New Availability Information). Journal article.
Reprint: Biocompatibility of Lipid Microcylinders: Effect on Cell Growth and Antigen Presentation in Culture. (Reannouncement with New Availability Information).
NR AD-A262 206/6/XAB; NMRI-92-125
9p; 1992
AU Rudolph, A. S.; Stilwell, G.; Cliff, R. O.; Kahn, B.; Spargo, B. J.
AN 1996(16):09439 NTIS

=> d ab 8,26,27,39,54,82,92,103,104,126

L61 ANSWER 8 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
AB AUTHOR ABSTRACT - The major growth seen in the biotechnology industry in recent decades has largely been driven by the exploitation of genetic engineering techniques. The initial benefits have been predominantly in the biomedical area, with products such as vaccines and hormones that have received broad public approval. In the environmental biotechnology and industrial ecology sectors, biotechnology has the potential to make significant advances through the use ofgenetically modified (GM) microbial inoculants that can reduce agri-chemical usage or remediate polluted environments. Although many GM inoculants have been developed and tested under laboratory conditions, commercial exploitation has lagged behind. Here, we review scientific and regulatory requirements that must be satisfied as part of that exploitation process. Particular attention is paid to new European Union (EU) regulations (Directives) that govern the testing and release of genetically modified organisms and microbial plant protection inoculants in the EU. With regard to the release ofGM inoculants, the impact of the inoculant and the fate of modified genesare important concerns. Long term monitoring of release sites is necessaryto address these issues. Data are reported from the monitoring of a site 6years after release of GM Sinorhizobium meliloti strains. It was found thatdespite the absence of a host plant, the GM strains persisted in the soilfor at least 6 years. Horizontal transfer and microevolution of a GM plasmid between S. meliloti strains was also observed. These data illustrate theimportance of assessing the long-term persistence of GM inoculants. (8 pages)

L61 ANSWER 26 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
AB The invention relates to compns. and methods for delivering a virus vector to an animal. The compns. include compns. which comprise a matrix having a virus vector bound at the exterior surface thereof in a physiol. reversible manner. The invention also includes methods of making such compns., including particles, devices, bulk materials, and other objects which comprise, consist of, or are coated with such compns. Methods of delivering a virus vector to an animal tissue are also described.

L61 ANSWER 27 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
AB The invention relates to compns. and methods for delivering a virus vector to an animal. The compns. include compns. which comprise a hydrogel matrix (e.g. a collagen matrix which can comprise a poloxamer or an alginate) containing a virus vector therein in a transfectious form. The invention also includes methods of making such hydrogel precursor mixts. and hydrogel matrixes, including particles, devices, bulk materials, and other objects which comprise, consist of, or are coated with such mixts. or matrixes. The invention further relates to compns. comprising a

hydrogel precursor mixture having a virus vector suspended therein, which, when administered to an animal, gel to form a hydrogel matrix containing a virus vector therein in a transfectious form. Methods of delivering a virus vector to an animal tissue are also described.

L61 ANSWER 39 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
AB A new genetically engineered Pseudomonas sp. biological control agent that can control attacks of crop plants by pathogenic fungi e.g. Rhizoctonia sp. and Pythium sp., and aggressively compete with indigenous bacteria and microflora in the plant rhizosphere, is produced from Pseudomonas fluorescens parent strains modified using lemA and gacA regulatory genes and/or genes involved in the synthesis of the fungicide metabolite phenazine-1-carboxylic acid and/or pyrrolnitrin (PN) to enhance production of the fungicide metabolites. The strains can be applied to e.g. cotton (Gossypium hirsutum), wheat (Triticum aestivum) and bean crop plants, seeds or soil. The preferred strains are as follows: gacA and lemA regulatory genes are transformed into transposon mutant of wild-type P. fluorescens; the first base in gacA is changed from thymidine to adenine; genes involved in PN synthesis are linked to a strong constitutive bacterium promoter; the strain is transformed with a plasmid containing lemA and gacA, optionally with a pmATCD cluster; the strain is transformed with a mutant gacA gene, etc. (others specified). (85pp)

L61 ANSWER 54 OF 155 HCAPLUS COPYRIGHT 2009 ACS on STN
AB This application relates to tetracycline-controlled eukaryotic expression vectors adapted for use in gene therapy or gene immunization having pos. feedback regulation. The vector constructs comprise a single transcription unit comprising a first cistron encoding a desired gene product and a second cistron encoding the tracycline-controlled activator, and an internal ribosome entry site positioned between the cistrons. Depending on the configuration of the tetracycline-controlled activator-responsive promoter, tetracycline can be used to induce or inhibit transcription. By adjusting the position of the tetracycline operator sequence in relation to the TATA box, the resultant promoter can be modified to function in either pos. or neg. regulation by tetracycline. This general invention is exemplified in a hCMV-IE based plasmid vector. Plasmid pUHD10-3 containing the chimeric tetracycline operator sequence (tetO)/hCMV-IE TATA box, and pUHD15-1, expressing the tetracycline-controlled activator (tTA) were used to construct the plasmid vector. The tTA can be a fusion protein for example one that is modified so that it is localized to the eukaryote nucleus.

L61 ANSWER 82 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
AB Liquid-culture parameters (pH, temperature and C-source) were manipulated to control phenazine-1-carboxylic acid (PCA) production by the take-all biological control agent Pseudomonas fluorescence 2-79 NRRL B-15132. The optimized fermentor medium contained (per l) 2 g K2HPO4, 2 g KH2PO4, 0.03 g cytosine, 0.01 g adenine, 0.01 g thymine, 4.4 mg ZnSO4.7H2O, 11 mg CaCl2.2H2O, 10 mg MnCl2.4H2O, 2 mg(NH4)6Mo7O24.4H2O, 2.4 mg H3BO3, 0.05 g EDTA, 0.05 mg folic acid, 0.05 mg biotin, 0.05 mg cyanocobalamin, 0.1 g MgSO4.7H2O, 0.01 g NaCl, 0.01 g FeSO4.7H2O and C- and N-sources. Concentrated stock solutions of buffer, Mg2+/Na+, Fe2+, trace minerals, purines/pyrimidines and vitamins were prepared to compose 0.8, 0.2, 1, 1.5, 0.6 and 2% of the total medium volume, respectively. Controlled-pH (7 and 8) studies of C- and N-source utilization for growth and PCA production were carried out in a 2 l working volume fermentor at 25 deg, 1,000 ml/min air flow and 300 rpm. High, moderate or low PCA productivities were observed at 25-27, 29-32.5 or 34 deg, respectively. PCA accumulation per unit biomass reached 0.31 g/g on glucose, 0.16 g/g on glycerol and xylose and 0.09 g/g on fructose. (23 ref)

L61 ANSWER 92 OF 155 NTIS COPYRIGHT 2009 NTIS on STN
AB There are different possibilities of biological containment to restrict and to prevent the dispersal of bacterial recombinant DNA after the deliberate release: The use of plasmids with a confined host-range neither transferable by conjugation nor mobilisable, has to be mentioned in this contents. Binding of the recombinant DNA to a specific host is more efficient by integrating the genetical material into the bacterial chromosome. To prevent the dispersal of the organism itself mutations are introduced that lower the competitiveness with the natural bacterial flora leading to a long-term elimination. Another way to eliminate the deliberate released bacteria is the inducible expression of lethal genes. There are some serious problems with the formation of resistant bacteria and effective practical use of the inducing molecules. Considering this none of the introduced systems can said to be a practicable biological containment-mechanism. Genetically modified poxviruses are used for the control of rabies. In this case the biological containment is based on the inactivation of the thymidin-kinase-gene (tk), which is important for the virulence of the virus. The inactivation of the tk-gene is due to the insertion of the glycoprotein G-gene of the rabies-virus. This leads to the expression of the glycoprotein G-gene inducing the production of antibodies against the rabies virus. Baculoviruses are used to control insect pest and valid to have highly restricted host ranges. The biological containment is based on the reduction of the ecological fitness by inactivation of the polyhedrin-codinggene. Biological containment of plants (Nicotiana tabacum, Brassica napus) is tried to be achieved by the induction of male sterility. The cells of the tapetum are destroyed by the induction of ribonuclease genes (TA29-RNase T1 or TA29-Barnase). (orig.). (Copyright (c) 1995 by FIZ. Citation number 95:003492.)

L61 ANSWER 103 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
AB Nonantibiotic and autoselection markers for genetically engineered mi croorganism (GEM) vector construction include bialaphos or glyphosate herbicide resistance, resistance to mercuric salts and organomercuri als (useful for GEMs used for cleanup purposes), growth on lactose an d autoselection in thyA, asd or ssb strains. Many vectors capable of replicating in Gram-negative bacteria are based on IncQ, IncP1 and I ncW replicons. However, nearly all broad-host-range plasmids carry a ntibiotic-resistance markers, are unstable in the absence of selectiv e pressure and cause physiological stress. The use of transposons in stead of plasmids as vectors may overcome these problems. A series o f transposon Tn5 and transposon Tn10 derived minitransposons vectors containing nonantibiotic selection determinants has been developed. Expression of recombinant genes in the field can be regulated by mani pulating expression to be affected by a signal present in the contami nated location, or by the use of stationary-phase promoters. Systems are being developed for the biological containment of GEMs in the en vironment. (83 ref)

L61 ANSWER 104 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
AB There is considerable potential for the genetic manipulation both of the biosynthesis and uptake of siderophores and the production of fungicides by disease-suppressive pseudomonad strains. Use of constitutive siderophore-producing strains, the acquisition of additional ferric siderophore receptor genes, and transfer of fungicide biosynthetic genes to nonproducers offer ways to improve the capabilities of inoculant strains. The development of a stable vector system is a prerequisite for environmental release of genetically engineered Pseudomonas spp. The thymidylate-synthase (TS, EC-2.1.1.45) gene (

thyA) of Lactococcus lactis has been used as a positive selectable marker in various microorganisms. The thy system is based on a host strain which is deficient in TS activity and a vector containing a copy of the L. lactis thyA gene. Since TS activity is essential for de novo DNA synthesis, the vector containing a copy of the gene is stably maintained. The thy system has been demonstrated in Rhizobium meliloti but has not yet been successfully adapted to Pseudomonas sp. (25 ref)

L61 ANSWER 126 OF 155 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
AB The possibility of selecting double revertants of Thy+Tdr in Bacillus thuringiensis was investigated. Bac. thuringiensis var. galleriae 351 and mutant derivatives thy (thymine) dra (deoxyriboaldolase) and thy drm (phosphodeoxyribomutase) were studied. There was a variation in the phenotype of the rough colony morphology (R) Thy+ thymidine resistant (Tdr)-forms selected by 4 different methods; thymine prototrophy, resistance to thymidine, phage Tg4 and tetracycline. R Strains could be selected during the selection of Thy+ Tdr variants. The drm genes behaved like the dra gene, although a strain with the control marker preserved in the R form was not obtained, so that the observed reversion of the drm gene during the S to R transformation was not conclusively established. The genetic determinants responsible for antibiotic resistance may be involved in the regulation of the activity of this additional genetic material. (18 ref)

=> fil .becpat
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 390.81 391.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE -2.46 -2.46

FILES 'BIOTECHDS, HCAPLUS, WPIDS' ENTERED AT 22:18:17 ON 15 MAR 2009

3 FILES IN THE FILE LIST

=> s (l36 or l48) and wo/pc and pry<=2002 and py>=2003 range=2003,
FILE 'BIOTECHDS'
39684 WO/PC
33881 PRY<=2002
(PRY<=2002)
148621 PY>=2003
(PY>=2003)
L62 2 (L28 OR L40) AND WO/PC AND PRY<=2002 AND PY>=2003

FILE 'HCAPLUS'
451994 WO/PC
784236 PRY<=2002
7587616 PY>=2003
L63 4 (L31 OR L43) AND WO/PC AND PRY<=2002 AND PY>=2003

FILE 'WPIDS'
829294 WO/PC
1647855 PRY<=2002
5628701 PY>=2003
(PY>=2003)
L64 2 (L35 OR L47) AND WO/PC AND PRY<=2002 AND PY>=2003

```
TOTAL FOR ALL FILES
L65          8 (L36 OR L48) AND WO/PC AND PRY<=2002 AND PY>=2003

=> dup rem l65
PROCESSING COMPLETED FOR L65
L66           7 DUP REM L65 (1 DUPLICATE REMOVED)

=> d tot

L66  ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Sequences of human and mouse telomerase reverse transcriptase (TERT)
     promoter and their uses in driving expression of therapeutic gene and drug
     screening
SO   U.S., 53 pp., Cont.-in-part of U.S. Ser. No. 974,584.
     CODEN: USXXAM
IN   Morin, Gregg B.; Lichtsteiner, Serge P.; Vasserot, Alain P.; Adams, Robert
     R.; Andrews, William H.
AN   2004:669756  HCAPLUS
DN   141:200156
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 6777203           B1    20040817    US 1999-244438          19990204 <--
     US 6166178           A     20001226    US 1997-974549          19971119 <--
     CA 2362367           A1    20000810    CA 2000-2362367         20000204 <--
     CA 2362367           C     20040803
     WO 2000046355        A2    20000810    WO 2000-US3104          20000204 <--
     WO 2000046355        A3    20001130
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1147181           A2    20011024    EP 2000-917613          20000204 <--
     EP 1147181           B1    20040512
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     AU 761567            B2    20030605    AU 2000-38563           20000204 <--
     AT 266720            T     20040515    AT 2000-917613          20000204 <--
     ES 2220448           T3    20041216    ES 2000-917613          20000204 <--
     AU 763956            B2    20030807    AU 2001-47992           20010523 <--
     US 20040072787       A1    20040415    US 2003-674836          20030929 <--
     US 20060281106       A1    20061214    US 2006-411604          20060425 <--
     US 7378244           B2    20080527
     US 20080220438       A1    20080911    US 2008-109615          20080425 <--

L66   ANSWER 2 OF 7  BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI    Regulating production of a product in a cell, comprises inserting a
      regulatable catalytically active nucleic acid into a gene that produces
      the product or regulates the production of the product in the cell;
         vector-mediated reporter gene transfer and expression in host cell for
         gene therapy
AU    WILSON C; CLOAD S T; KEEFE A D
AN    2003-14785  BIOTECHDS
PI    WO 2003027310 3 Apr 2003

L66   ANSWER 3 OF 7  BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI    New human anti-MUC18 monoclonal antibodies, useful for treating a disease
      or condition associated with expression of MUC18 in a patient, e.g.
      tumors, cancers, and other malignancies;
```

vector-mediated gene transfer and expression in host cell and mouse hybridoma cell culture for monoclonal antibody production for use in cancer therapy
AU GUDAS J
AN 2003-21745 BIOTECHDS
PI WO 2003057838 17 Jul 2003

L66 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
IN Moro, Daniel G.; Callahan, Howard; Nowotnik, David P.
AN 2003:154225 HCAPLUS
DN 138:210299

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003015748	A2	20030227	WO 2002-US26083	20020816 <--
WO 2003015748	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030044446	A1	20030306	US 2001-931319	20010816 <--
US 6585997	B2	20030701		
CA 2459692	A1	20030227	CA 2002-2459692	20020816 <--
AU 2002326664	A1	20030303	AU 2002-326664	20020816 <--
AU 2002326664	B2	20080306		
EP 1418889	A2	20040519	EP 2002-761390	20020816 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU 2004001281	A2	20041129	HU 2004-1281	20020816 <--
HU 2004001281	A3	20080428		
JP 2005504763	T	20050217	JP 2003-520708	20020816 <--
NZ 531766	A	20051223	NZ 2002-531766	20020816 <--
CN 1738599	A	20060222	CN 2002-818327	20020816 <--
RU 2343903	C2	20090120	RU 2004-107575	20020816 <--
MX 2004001491	A	20040517	MX 2004-1491	20040216 <--
ZA 2004002067	A	20050528	ZA 2004-2067	20040315 <--

L66 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Method for identifying cellular targets using reporter constructs under the control of a enhancer or silencer
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
IN Erives, Albert J.; Starr, D. Barry
AN 2003:892334 HCAPLUS
DN 139:359906

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030211481	A1	20031113	US 2002-142370	20020508 <--
WO 2005078069	A1	20050825	WO 2003-US14788	20030509 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				

```
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2003304710        A1    20050901    AU 2003-304710         20030509 <--

L66  ANSWER 6 OF 7  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Sequences of smooth muscle myosin heavy chain promoter/enhancer for
     expressing polynucleotides specifically in smooth muscle cells in vivo
SO   U.S. Pat. Appl. Publ., 75 pp., Cont.-in-part of U.S. Ser. No. 600,319.
     CODEN: USXXCO
IN   Owens, Gary K.; Manabe, Ichiro
AN   2003:58708  HCAPLUS
DN   138:132218
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 20030017549       A1    20030123    US 2002-57726          20020124 <--
     US 6914136           B2    20050705
     WO 9936101           A1    19990722    WO 1999-US1038         19990115 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
             MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
             TR, TT, UA, UG, US, UZ, VN, YU, ZW
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6780610           B1    20040824    US 2000-600319         20000713 <--

L66  ANSWER 7 OF 7  WPIDS COPYRIGHT 2009       THOMSON REUTERS on STN
TI   Measuring abundance and expression of indicator and effector genes within
     biotreatment system, by sampling activated sludges and effecting
     polymerase chain reaction amplification of indicator and effector gene
     combinations from sample
PI   WO 2002085791   A2 20021031 (200305)* EN  47[8]                        <--
         RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
             NL OA PT SD SE SL SZ TR TZ UG ZM ZW
          W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
             DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
             KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
             RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
             ZW
     US 20030092020  A1 20030515 (200335)  EN                               <--
     EP 1414750      A2 20040506 (200430)  EN                               <--
          R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
             RO SE SI TR
     AU 2002257205   A1 20021105 (200433)  EN
     BR 2002009095   A  20040713 (200447)  PT                               <--
     MX 2003009732   A1 20040201 (200473)  ES                               <--
     CN 1531601      A  20040922 (200503)  ZH                               <--
     US 6849430      B2 20050201 (200511)  EN                               <--
     IN 2003CN01665  P4 20051125 (200607)  EN                               <--
     CN 1268767      C  20060809 (200682)  ZH                               <--
     AU 2002257205   B2 20060921 (200712)  EN                               <--
IN   CARSON D B; RICE J F


=> d ab 2-7

L66   ANSWER 2 OF 7  BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
```

AB DERWENT ABSTRACT:

NOVELTY - Regulating production of a product in a cell, is new.

DETAILED DESCRIPTION - Regulating production of a product in a cell comprises inserting a regulatable catalytically active nucleic acid (RCANA) into a gene that produces the product or regulates the production of the product in the cell, where the RCANA comprises a catalytic domain which modifies a transcript to alter its coding potential and a regulatory domain that recognizes an effector that alters the function of the catalytic domain, and contacting the regulatory domain with an effector to regulate production of the product. INDEPENDENT CLAIMS are also included for the following: (1) regulating a biological pathway in cell; and (2) screening a population of cells for a cell that produces a bioproduct.

WIDER DISCLOSURE - Also disclosed are the following: (1) isolating a regulatable catalytically active nucleic acid (RCANA) created by randomizing at least one nucleotide in the catalytic domain of a catalytically active nucleic acid to create a nucleic acid pool; (2) modulating expression of a nucleic acid by providing a polynucleotide that is regulated by a peptide; and (3) an RCANA construct with a regulatable oligonucleotide sequence having a regulatory domain.

BIOTECHNOLOGY - Preferred Method: In regulating production of a product in a cell, the production of the product is fully inhibited, or increased compared to a normal control level. The production of the product is partially inhibited according to the concentration of the effector. The concentration of the effector modulates the activity of the catalytic domain of the regulatable catalytically active nucleic acid (RCANA), where the RCANA blocks or activates the expression of the gene. The effector is the product, a feedback inhibitor of the gene, or an intermediate in a metabolic pathway. The product is produced in a metabolic pathway that is being regulated, or is an intermediate in a metabolic pathway. The biological pathway is preferably a metabolic pathway. The effector is endogenous or exogenous to the cell. The effector or the product is a protein, an enzyme, a protein pharmaceutical, a metabolite, a drug, a dye, a vitamin, a food additive, a chemical additive, a pesticide, an insecticide, a feed compound, or a waste product. The drug is an antibiotic, an anticancer drug, an antifungal, a cholesterol-lowering drug, or an immunosuppressant. Preferably, the effector is an endproduct of a biosynthetic process. Regulating a biological pathway in cell comprises: (a) inserting a first RCANA into a first gene that produces a first product or regulates the production of the first product in the biological pathway in a cell, where the first RCANA comprises a catalytic domain which catalyzes cleavage of the RCANA or excision of the RCNA from gene in which it is inserted followed by ligation of the gene at 5' and 3' ends of cleavage site, and a regulatory domain which recognizes an effector that activates a function of the catalytic domain; (b) inserting a second RCANA into a second gene that produces a second product or regulates the production of the second product in the biological pathway in the cell, where the second RCANA comprises a catalytic domain which catalyzes cleavage of the RCANA or excision of the RCNA from gene in which it is inserted followed by ligation of the gene at 5' and 3' ends of cleavage site, and a regulatory domains which recognizes an effector that activates a function of the catalytic domain; and (c) contacting the first regulatory domain with a first effector to regulate production of the first product, and contacting the second regulatory domain with a second effector to regulate production of the second product. The combination of the first and second effectors controls the flux of metabolites through the biological pathway. The biological pathway is a biosynthetic or a metabolic pathway. The biological pathway is fully inhibited or partially inhibited according to the concentration of the first and second effectors. The first product is the second effector. The method further comprises inserting a third RCANA into a third gene that

produces a third product or regulates the production of the third product in the biological pathway in the cell, where the third RCANA comprises a catalytic domain which catalyzes cleavage of the RCANA, or excision of the RCANA from gene in which it is inserted followed by the ligation of the gene at 5' and 3' ends of cleavage site, and a regulatory domain which recognizes an effector that activates a function of the catalytic domain. The first and second RCANAs block or activate expression of the first and second gene. Screening a population of cells for a cell that produces a bioproduct comprises inserting an RCANA into a reporter gene in the population of cells, such that the RCANA is regulated by the bioproduct, where expression of the reporter gene indicates the production of the bioproduct by the cell. The method further comprises isolating the cell that produces the bioproduct. The reporter gene is green fluorescent protein, thymidylate synthase, or beta lactamase.

ACTIVITY - None given. No biological data given.

MECHANISM OF ACTION - Gene Therapy.

USE - The methods are useful for regulating a biological pathway in cell, or regulating production of a product in a cell. The regulatable catalytically active nucleic acids (RCANAs) are useful as regulatory elements to control the expression of genes in a metabolic pathway, or as regulated selectable markers to increase a selective pressure favoring or disfavoring production of a targeted bioproduct. The RCANAs are also useful for in vitro or in vivo sensing or detection, and in gene therapy.

EXAMPLE - No relevant example given. (128 pages)

L66 ANSWER 3 OF 7 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN

AB DERWENT ABSTRACT:

NOVELTY - An isolated monoclonal antibody comprising a heavy chain amino acid or a heavy chain variable domain, where the antibody binds to MUC18, is new.

DETAILED DESCRIPTION - An isolated monoclonal antibody comprising a heavy chain amino acid comprising an amino acid sequence selected from 10 fully defined sequences of 117-123 amino acids, as given in the specification and a heavy chain variable domain encoded by a nucleic acid molecule comprising a sequence selected from 10 fully defined sequences of 352-370 base pairs, as given in the specification, is new.

WIDER DISCLOSURE - Also disclosed as new are: (1) an isolated nucleic acid encoding the antibody; (2) a vector comprising the nucleic acid; (3) a host cell transformed with the nucleic acid molecule; and (4) producing the antibody.

BIOTECHNOLOGY - Preferred Antibody: The monoclonal antibody is a fully human antibody, and further comprises a light chain amino acid comprising a sequence selected from 10 fully defined sequences of 107-112 amino acids, as given in the specification. The antibody is conjugated to a therapeutic agent, e.g. radioisotope, or to a cytotoxic agent, e.g. ricin. The antibody may further comprise a light chain variable domain encoded by a nucleic acid molecule comprising a sequence selected from 10 fully defined sequences of 322-340 base pairs, as given in the specification.

ACTIVITY - Cytostatic. Human patients with tumors were injected with anti-MUC18 antibody, and at periodic times during the treatment, patients were monitored to determine the progression of the tumor, particularly to monitor growth and metastasis. A tumor patient treated with anti-MUC18 antibodies showed lower levels of tumor growth and metastasis compared to the level of tumor growth and metastasis of tumors in patients treated with control antibodies.

MECHANISM OF ACTION - MUC18 inhibitor. No biological data given.

USE - The monoclonal antibody is useful for treating a disease or condition associated with the expression of MUC18 on the cell surface, e.g. tumors (e.g. melanoma, esophageal, pancreatic or colorectal tumors),

carcinomas (e.g. cervical carcinomas and cervical intraepithelial squamous and glandular neoplasia), and cancers (e.g. colorectal, breast or lung cancer) and other malignancies.

ADMINISTRATION - Dosage is 0.1-50 (0.3-20) mg/kg body weight per day. Administration can be through injection or infusion by intravenous, intraperitoneal, intracerebral, subcutaneous, intramuscular, intraocular, intraarterial, intracerebrospinal, intralesional routes, inhalation, or by sustained systemic release.

EXAMPLE - Monoclonal antibodies against MUC18 were developed by sequentially immunizing XenoMouse mice. Initial immunization was with 5 to the power of 6 SK-MEL-28 cells admixed with Complete Freund's Adjuvant. Subsequent boosts were made first with 5 to the power of 6 SK-MEL-28 cells with Incomplete Freund's adjuvant (IFA), followed by 4 injections with 5 microgram of soluble MUC18-human IgG2 Fc fusion protein admixed with IFA, then a final boost of 10 microgram soluble MUC18-human IgG2 Fc fusion protein without adjuvant. Each mouse was immunized either at the base of the tail by intraperitoneal injection or via hind footpad injection with MUC18 recombinant antigen followed by generation of a large number of candidate monoclonal antibodies. Animals were immunized on days 0, 4, 7, 10, 14, 17 and 20; and 4 days later, fusions were performed. After fusion, cells were resuspended in Dulbecco's modified Eagle medium (DMEM), 15 % fetal calf serum (FCS) containing HAT (hypoxanthine, aminopterin and thymidine), and supplemented with L-glutamine, pen/strep, OPI (oxaloacetate, pyruvate, bovine insulin) for culture at 37 degrees centigrade. Cells were plated on 96-well tissue culture plates, and maintained in HAT supplemented media for 2 weeks. Hybridomas were selected and screened for antigen reactivity by Enzyme-Linked Immunosorbent Assay (ELISA). Cloning was performed on selected antigen-positive wells using limited dilution plating. Assay results identified the following anti-MUC18 antibodies: c3.19.1, c6.11.3, c3.10, c3.22, c3.27, c3.45, c3.65, c6.1, c6.9, c6.2 and c6.12. (78 pages)

L66 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN

AB The present invention relates to a layered pharmaceutical delivery device for the administration of pharmaceuticals or other active compds. to mucosal surfaces. The device may also be used by itself without the incorporation of a therapeutic. The device of the present invention consists of a water-soluble adhesive layer, a non-adhesive, bioerodible backing layer and one or more pharmaceuticals if desired in either or both layers. Upon application, the device adheres to the mucosal surface, providing protection to the treatment site and localized drug delivery. The "Residence Time", the length of time the device remains on the mucosal surface before complete erosion, can be easily regulated by modifications of the backing layer.

L66 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN

AB The present invention is directed to nucleic acid constructs and their use in identifying cellular factors that function in various cellular processes involving gene expression. Such factors include those that participate in signaling pathways to regulate cellular gene expression. These factors may be the targets of known therapeutic agents, novel targets for a test compound, or amenable to altered expression to modulate cellular processes. In a particular embodiment, luciferase reporter construct containing luciferase gene under the control of a PSA regulatory module operably linked to a Simian Virus 40 (SV40) basal promoter, IRES and hygromycin resistance is co-expressed with vectors expressing a prostate cDNA expression library in an androgen dependent prostate cell line for screening pos. or neg. regulatory mols. in the bicalutamide (androgen receptor antagonist). In another particular embodiment, a HSV thymidylate kinase gene can be used to replace hygromycin resistance gene or expressed from a second "control" construct under the control of a

basal SV40 promoter, and latter setting is useful for the screening of cDNAs encoding other factors, such as a membrane associated transporter that removes bicalutamide from the cell. In further embodiments, the silencer can be used to replace the PSA regulatory module.

L66 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
AB The present invention provides isolated or recombinant polynucleotides which comprise a smooth muscle myosin heavy chain (SM-MHC) promoter/enhancer sequence capable of conferring smooth muscle specific expression in vivo and other regulatory elements of smooth muscle cells (SMC). The invention more particularly relates to methods for the targeted knockout, or over-expression, of genes of interest within smooth muscle cells or within a subtype of smooth muscle cells. The invention further relates to methods of conferring polynucleotide expression in vivo specifically in smooth muscle cells or in subtypes of smooth muscle cells. The invention further provides expression vector comprising SM-MHC promoter/enhancer sequence, genetic engineered host cells comprising an expression vector, and transgenic animals.

L66 ANSWER 7 OF 7 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
AB WO 2002085791 A2 UPAB: 20050903
NOVELTY - Determining the levels of abundance and expression of an indicator and effector gene combination within a biotreatment system (BS), comprises isolating DNA and mRNA from microorganisms from a stream of a BS, determining levels of indicator gene abundance by quantitative polymerase chain reaction (qPCR) analysis of DNA and levels of effector gene abundance by qRT-PCR analysis of mRNA.

DETAILED DESCRIPTION - Determining the levels of abundance and expression of an indicator and effector gene combination within a biotreatment system (BS), comprises isolating DNA and mRNA from microorganisms from a microorganism-containing stream of a BS, determining levels of indicator gene abundance by quantitative polymerase chain reaction (qPCR) analysis of DNA and levels of effector gene abundance by qRT-PCR analysis of mRNA, where indicator and effector genes are same or different.

INDEPENDENT CLAIMS are also included for the following:

(1) optimizing a waste treatment system which comprises sampling wastewater from a waste treatment system, collecting solids from the sample, isolating DNA and RNA from the solids, performing qPCR or competitive qPCR on the DNA to determine indicator gene abundance, performing quantitative RT-PCR (qRT-PCR) on the RNA to determine effector gene expression, where the indicator gene abundance correlates with the active microbial content (AMC) of the sample and the effector gene expression correlates with the active bioremedial content (ABC) of the sample, and the system is perturbed and repeating the steps until the AMC and ABC are within an empirically determined optimal operating range; and

(2) controlling BS, by sampling a microorganism -containing stream of BS, collecting microorganisms from the sample, isolating DNA and RNA from the microorganisms, determining AMC and ABC value for the sample by qPCR analysis of the DNA or RNA, respectively, or determining a specific bioremedial content (SBC) value for the sample by qPCR analysis of the DNA and qRT-PCR analysis of the RNA, and setting a target AMC, ABC or SBC value for the sample, comparing the determined AMC, ABC or SBC value to the target AMC, ABC or SBC value, and adjusting control processes to make the determined AMC, ABC or SBC values closer to the target values when repeating the above steps.

USE - Useful for determining levels of abundance and expression of an indicator and effector gene combination within a biotreatment system, controlling a biotreatment system and for optimizing a waste treatment system. The treatment system is a continuous flow activated sludge system, sequencing batch reactor system, a packed bed reactor system, immobilized bacteria system, fluidized bed reactor system, trickling filter system, or

a rotating biological contactor system.

ADVANTAGE - The monitoring method is more sensitive than conventional methods and is also more specific as live cells that actively contribute to the degradative potential are assayed. The PCR-based methods allow for accurate, quantitative measurement of both the amount of DNA present for a given indicator gene and levels of expression for the effector gene.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	48.61	439.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.46	-4.92

STN INTERNATIONAL LOGOFF AT 22:22:16 ON 15 MAR 2009